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Hemophagocytic syndromes represent extreme cases of uncontrolled immune activation resulting in severe
disease. Dysregulated CD8+ T cell responses are implicated in the pathogenesis of hemophagocytic
syndromes, although the mechanisms responsible for their hyperactivation are incompletely understood.
Identification of the signals promoting CD8+ T cell-mediated inflammation are therefore crucial to inform
the development of targeted immunotherapies for these diseases. Using murine models of hemophagocytic
syndrome, we investigated the interaction of activated CD8+ T cells arising in the context of systemic
inflammation with their surrounding environment, both in their response to antigen-independent cues and
their contribution to the cytokine storm. We found that the interleukin-33/ST2 pathway plays a key role in
amplifying inflammation above the threshold for fatal disease in a murine model of familial hemophagocytic
lymphohistiocytosis (FHL), generated by infection of perforin-deficient mice with lymphocytic
choriomeningitis virus (LCMV). ST2 intrinsically promotes LCMV-specific CD8+ and CD4+ T cell
proliferation and potentiates interferon-g (IFNg) production, thereby raising systemic quantities of IFNg to
lethal levels. Blockade of ST2 signaling protects FHL mice from mortality by acutely dampening the antiviral
T cell response and eventually leading to CD8+ T cell exhaustion, which further protects against chronic
wasting. In a different murine model of hemophagocytic syndrome, Toll-like receptor 9-induced macrophage
activation syndrome, we investigated liver-infiltrating lymphocyte populations induced by systemic
inflammation. We identified a unique population of effector-like interleukin-10-producing CD8+ T cells that
arises independently of antigen stimulation and accumulates within damaged liver. This work demonstrates
that the contribution of antigen-independent signals to CD8+ T cell activation is essential to the
pathophysiology of hemophagocytic syndromes and suggests that specific blockade of these signals may
provide therapeutic benefit.
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ABSTRACT 
 
THE ROLE OF ANTIGEN-INDEPENDENT SIGNALS IN CD8+ T CELL RESPONSES IN 
HEMOPHAGOCYTIC SYNDROMES 
Julia E. Rood 
Edward M. Behrens 
 
Hemophagocytic syndromes represent extreme cases of uncontrolled immune activation resulting 
in severe disease. Dysregulated CD8+ T cell responses are implicated in the pathogenesis of 
hemophagocytic syndromes, although the mechanisms responsible for their hyperactivation are 
incompletely understood. Identification of the signals promoting CD8+ T cell-mediated 
inflammation are therefore crucial to inform the development of targeted immunotherapies for 
these diseases. Using murine models of hemophagocytic syndrome, we investigated the 
interaction of activated CD8+ T cells arising in the context of systemic inflammation with their 
surrounding environment, both in their response to antigen-independent cues and their 
contribution to the cytokine storm. We found that the interleukin-33/ST2 pathway plays a key role 
in amplifying inflammation above the threshold for fatal disease in a murine model of familial 
hemophagocytic lymphohistiocytosis (FHL), generated by infection of perforin-deficient mice with 
lymphocytic choriomeningitis virus (LCMV). ST2 intrinsically promotes LCMV-specific CD8+ and 
CD4+ T cell proliferation and potentiates interferon-γ (IFNγ) production, thereby raising systemic 
quantities of IFNγ to lethal levels. Blockade of ST2 signaling protects FHL mice from mortality by 
acutely dampening the antiviral T cell response and eventually leading to CD8+ T cell exhaustion, 
which further protects against chronic wasting. In a different murine model of hemophagocytic 
syndrome, Toll-like receptor 9-induced macrophage activation syndrome, we investigated liver-
infiltrating lymphocyte populations induced by systemic inflammation. We identified a unique 
population of effector-like interleukin-10-producing CD8+ T cells that arises independently of 
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antigen stimulation and accumulates within damaged liver. This work demonstrates that the 
contribution of antigen-independent signals to CD8+ T cell activation is essential to the 
pathophysiology of hemophagocytic syndromes and suggests that specific blockade of these 
signals may provide therapeutic benefit. 
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CHAPTER 1: 
Introduction 
 
Among his many achievements as the “father of modern medicine”, Sir William 
Osler is credited with being the first to recognize the pathogenic role of the immune 
system in cases of sepsis, noting in 1904 that, “Except on few occasions, the patient 
appears to die from the body’s response to infection rather than from it” (Osler, 1904). 
While sepsis was a disease well-familiar to physicians as far back as ancient Greece, 
there was considerable controversy as to its cause, whether contagion or some 
poisonous byproduct produced during the septic “putrefaction” process (Funk et al., 
2009). Osler’s work was revolutionary in that it correctly identified the cause of the 
patient’s symptoms as the response of the patient’s own immune system, rather than the 
pathogen it was attempting to combat. Henceforth, physicians have increasingly 
recognized the power of the immune system – both its extraordinary healing ability and 
its sheer destructive capacity – in determining the health of its host. We are now more 
aware than ever that the immune system is inextricably linked, physically and 
functionally, to every tissue and organ system in the body: no anatomic compartment is 
devoid of cells with immunologic function or inaccessible to cytokines, and many 
immune cells possess regulatory function necessary for normal tissue homeostasis. It is 
no wonder that diverse symptoms can be attributed to dysfunction of this carefully 
orchestrated system, and diseases once thought to be unrelated to immunity are 
increasingly found to depend upon it. Investigation into the mechanisms underlying 
immune dysregulation is therefore necessary to illuminate normal immune networks and 
to shed light onto disease pathogenesis.  
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Regulation of the immune system 
 The immune system possesses an astonishingly diverse and powerful 
armamentarium for battling equally diverse and powerful pathogens. With such strength 
comes the need for careful regulation to ensure that this destructive potential is directed 
appropriately and suppressed when no longer necessary. Through billions of years of 
evolution, it has achieved this through exquisitely fine-tuned regulation in the form of 
feedback loops, redundancy, and double-checks. No single signal is able to activate all 
parts of the immune system; nor is one signal able to completely shut it off. Each step in 
the process, whether heightening or dampening the immune response, requires careful 
coordination among multiple networks of immune cells and their signaling mediators, 
each with its own positive and negative feedback mechanisms. 
 The immune response to viral infection offers a prime example of both the 
complexity of any immune response as well as the layers of regulation governing it. 
During the initial activation of the innate immune response, differentiation between 
harmful and harmless non-self entities is key, essentially determining whether or not to 
engage. This is achieved through coordinated detection of both “danger” signals and 
pathogen constituents. In the subsequent activation of the adaptive immune response, 
scaling and directing the response appropriately to the threat is critical. This is achieved 
through feedback loops governing both the expansion and contraction of effector CD8+ T 
cell responses, paralleling the rise and fall in viremia. We will treat each of these topics 
in detail, with particular attention placed on danger signals and CD8+ T cells, before 
turning to the central focus of this thesis: when these mechanisms become dysregulated 
and cause disease. 
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Initiation of the antiviral response: PAMPs and DAMPs 
From the moment a virus enters into a mammalian cell, the host becomes alerted 
to its presence through a series of genome-encoded receptors. Pattern recognition 
receptors (PRRs) detect conserved microbial motifs, collectively referred to as pathogen-
associated molecular patterns (PAMPs) (Iwasaki and Medzhitov, 2015). Exposure of 
viral nucleic acid within the cell activates cytosolic PRRs such as RIG-I and MDA-5, 
which initiate a potent type I interferon response that converts both the infected cell and 
its neighbors to an antiviral state. Detection of viral nucleic acid by a dendritic cell (DC) 
activates endosomal Toll-like receptors (TLRs), such as TLR3, TLR7, or TLR9, thereby 
initiating a series of maturation events that transforms the DC into a professional antigen 
presenting cell (APC).  
However, since harmless commensal microbes are also capable of activating 
these PRRs, the immune system has evolved another layer of regulation to ensure that 
only true evidence of danger elicits a response. Such danger-associated molecular 
patterns (DAMPs) or alarmins are associated with, but are distinct from, PAMPs. While 
PAMPs are inherently derived from non-mammalian sources, DAMPs are endogenous, 
host-derived signals (Matzinger, 2002). It is therefore important that they be carefully 
separated from potential responder cells, to prevent spontaneous induction of 
inflammatory responses in the absence of danger, and only be released in the presence 
of a legitimate threat. Thus, DAMPs are typically sequestered inside host cells, hidden 
from the immune system, and released only under conditions of cellular stress or 
necrosis. The immune system has evolved to react to these signs of uncontrolled cell 
death or toxicity with an inflammatory response, since tissue damage either indicates the 
presence of some infectious insult or sterile trauma requiring wound healing. The danger 
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signal that DAMPs provide therefore plays an important role in conditioning the immune 
response to PAMPs and other immunostimulatory signals.  
 
IL-33 and ST2 
As an example, interleukin-33 (IL-33), a member of the IL-1 family of cytokines, is 
a prototypic DAMP (Martin, 2016). Similar to its relatives IL-1β and IL-18, IL-33 lacks a 
signal peptide and therefore cannot be secreted in the manner of a “traditional” cytokine 
(Carriere et al., 2006). However, whereas IL-1β and IL-18 exist in the cytosol and require 
inflammasome-mediated activation of caspase-1 to undergo proteolytic processing and 
be released in active form, IL-33 is constitutively active and independent of caspase-1 
(Cayrol and Girard, 2009; Talabot-Ayer et al., 2012). Instead, it is targeted to the nucleus 
via its N-terminal nuclear localization sequence, and only thought to be released upon 
necrotic cell death, as apoptosis leads to its inactivation by caspases 3 and 7 
(Baekkevold et al., 2003; Carriere et al., 2006; Luthi et al., 2009). IL-33 is constitutively 
expressed by epithelial and endothelial cells, among others, making it an ideal alarm 
signal of compromised barrier integrity (Moussion et al., 2008; Pichery et al., 2012). 
Additionally, its expression can be upregulated by TLR activation and other inflammatory 
signals in anticipation of enhanced cell death and release (Palmer et al., 2009; Polumuri 
et al., 2012; Shimosato et al., 2010). Its activity can be further enhanced 10- to 100-fold 
when cleaved by proteases released by first responder cells such as mast cells and 
neutrophils (Lefrançais et al., 2014; Lefrançais et al., 2012).  
The receptor for IL-33, ST2 (encoded by the Il1rl1 gene), is expressed by a wide 
array of immune cell subsets (Schmitz et al., 2005). Like other IL-1 family members, IL-
33 signals by binding to its specific receptor on the plasma membrane, which then 
recruits the common IL-1 receptor accessory protein (IL-1RAcP) through TIR domain 
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interactions (Liu et al., 2013a). This leads to the recruitment of the adaptor molecule 
MyD88, and subsequently IRAK family members and TRAF6, culminating in the 
activation of the NF-κB and p38 MAPK pathways – not unlike the TLR signaling pathway 
(Schmitz et al., 2005). The convergent signaling pathways shared by TLRs and IL-1Rs 
provide an important mechanism for promoting synergy between PAMP and DAMP 
signaling.  
IL-33 has traditionally been appreciated as an important component of allergic 
and anti-helminth responses through its ability to activate Th2 cells, ILC2s, mast cells, 
eosinophils, and basophils, and to promote the release of IL-4, IL-5, and IL-13 
(Allakhverdi et al., 2007; Liew et al., 2010; Schmitz et al., 2005). Whether IL-33 plays a 
role in promoting other types of inflammation, including systemic inflammatory diseases 
such as hemophagocytic syndromes, is just beginning to be investigated (Palmer and 
Gabay, 2011). It is a major focus of this thesis that will be revisited shortly. 
 
The antiviral effector CD8+ T cell response 
By virtue of their specialized ability to eliminate virally-infected cells, CD8+ T cells 
comprise a key component of the immune response to viral infections (Janeway et al., 
2001). In order to be recruited into the antiviral response, naïve CD8+ T cells first require 
activation by professional APCs, such as DCs, cross-presenting viral peptide. 
Recognition of cognate antigen in the context of major histocompatibility complex Class I 
(MHC I) through specific interaction with its T cell receptor (TCR) provides the first 
activating signal – termed Signal 1 – to the CD8+ T cell. An additionally required form of 
verification, Signal 2, is provided by ligation of costimulatory molecules expressed by the 
DC (e.g. CD80) to CD28 on the T cell surface. This amplifies the intracellular signal 
downstream of TCR sufficiently to exceed the threshold for activation. Lastly, cytokines 
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released by the APC or other nearby cells, such as IL-12 or type I interferons (IFN-I), 
bind cytokine receptors on the CD8+ T cell and provide Signal 3, which influences the 
attributes of subsequent CD8+ T cell effector differentiation. Together, these three 
signals activate CD8+ T cells to undergo a cascade of massive transcriptional, 
epigenetic, and metabolic changes to enable differentiation into cytotoxic effector cells 
(Kaech and Cui, 2012).  
These newly activated CD8+ T cells clonally expand and upregulate effector 
molecules such as the cytokines interferon-γ (IFNγ), tumor necrosis-α (TNFα), and 
interleukin-2 (IL-2). Additionally, they accrue cytotoxic granules containing perforin, a 
pore-forming protein, and serine proteases such as granzyme B (Voskoboinik et al., 
2010). Upon encounter with its cognate viral antigen, nestled in the groove of MHC I 
expressed on an infected target cell, an effector CD8+ T cell becomes activated to 
secrete cytokines and lyse the target cell. In order to direct these effector functions 
toward the infected cell, the CD8+ T cell polarizes, shuttling its cytotoxic granules toward 
the immunological synapse that conjugates it to the target cell. Exocytosis of the 
cytotoxic granules leads to the release of their contents into the immunological synapse. 
Perforin subsequently forms a hole in the plasma membrane of the target cell, through 
which granzyme B enters and proteolytically activates caspases 3 and 7 to initiate 
apoptosis. In addition to eliminating virally-infected cells, CD8+ T cells also mediate 
cytotoxicity against antigen-bearing APCs (Guarda et al., 2007; Hermans et al., 2000; 
Yang et al., 2006). This provides a negative feedback mechanism that tunes the 
magnitude of the effector CD8+ T cell response proportionally to the amount of antigen 
present. Because the ability to eliminate virally-infected cells and other sources of 
antigenic stimulation is a crucial component of the antiviral immune response, functional 
defects in cytotoxicity can have devastating consequences for the host. However, the 
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greatest danger in such cases is caused not by uncontrolled viral replication, but by 
dysregulation of the immune response. 
 
Hemophagocytic syndromes 
Given the potency of the immune response and its inherent interconnectedness, 
it is not surprising that perturbations to this normal, tidy order can prove catastrophic. 
Any force great enough to overwhelm the normal negative feedback mechanisms and 
override checks on the system – whether derived from within the host or without – can 
lead to a rapidly escalating cycle of immune activation, fueled by positive feedback. 
When this type of immune dysregulation occurs on an organism-wide level, it is 
classified as a hemophagocytic syndrome or cytokine storm disorder, a collective term 
for potentially fatal disorders of systemic hyperinflammation.  
Excepting sepsis, the first description of a hemophagocytic syndrome was 
reported in 1939 by Scott and Robb-Smith as “histiocytic medullary reticulosis,” a rapidly 
fatal disease characterized by unremitting fever, wasting, hepatosplenomegaly, 
pancytopenia, jaundice, and purpura (Scott and Robb-Smith, 1939). At the time, the 
greatest insight into disease came from histology; as Scott and Robb-Smith themselves 
noted, “where the cause of a morbid process is unknown its diagnosis commonly rests 
on the changes in the patient’s tissues, the ultimately analysis of which must be 
microscopical.” Thus, the histopathologic pattern they described in their four cases, 
“progressive cellular hyperplasia throughout the hematopoietic and lymphatic tissues” of 
lymphocytes and “histiocytes actively engaged in phagocytosis of erythrocytes” 
(hemophagocytes), plus the accompanying clinical syndrome, came to define this 
disease for the next several decades and provided the name by which it later became 
known, hemophagocytic lymphohistiocytosis.  
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While Scott and Robb-Smith were correct in distinguishing hemophagocytic 
lymphohistiocytosis from other diseases of aberrant leukocyte proliferation, they failed to 
realize that even the uniform histopathologic pattern they described was actually 
representative of the wider spectrum of hemophagocytic syndromes. Today, clinicians 
appreciate that the eponymous hemophagocyte is a non-specific hallmark of immune 
activation and that diverse inciting factors and disease processes lead to the 
development of distinct forms of hemophagocytic syndrome (Weaver and Behrens, 
2014). At one end of the spectrum exist primary, or genetic, forms of disease resulting 
from monogenic lesions: familial hemophagocytic lymphohistiocytosis (FHL), Griscelli 
syndrome type 2, Chédiak-Higashi syndrome, Hermansky-Pudlak syndrome type 2, and 
X-linked lymphoproliferative disease. Towards the other end exist secondary, or 
acquired, forms in which hemophagocytic syndrome results from an underlying 
condition, such as infection (particularly with Epstein-Barr virus, EBV), malignancy, or 
autoimmune or autoinflammatory disease (in which case it is referred to as macrophage 
activation syndrome, MAS). The extreme end of this spectrum includes hemophagocytic 
syndrome-like conditions that are triggered almost entirely by environmental, rather than 
host, factors: cytokine release syndrome occurring after infusion of chimeric antigen 
receptor T cells, toxic shock syndrome, and sepsis (Canna and Behrens, 2012). 
 The epidemiology of hemophagocytic syndrome naturally varies according to the 
underlying cause. Primary forms are more common among children, with 70-80% of FHL 
cases presenting within the first year of life (Aricò et al., 1996; Sieni et al., 2014). 
However, late-onset cases of FHL have been reported in adolescence and adulthood 
(Allen et al., 2001; Clementi et al., 2002), and the severity of the underlying genetic 
mutation likely determines the age of presentation (Jessen et al., 2013; Sieni et al., 
2014). FHL is also rare, occurring in an estimated 1 per 100,000 children in the US, but 
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has higher prevalence in geographic regions where parental consanguinity is more 
common (Niece et al., 2010; Sieni et al., 2014). Secondary forms of hemophagocytic 
syndrome, which are more common among adult populations, occur at unknown 
incidence and are likely underdiagnosed (Schram et al., 2016).  
Despite their distinct etiologies, hemophagocytic syndromes are united by a 
remarkably consistent clinical picture, the manifestation of immune hyperactivation. Due 
to the high degree of clinical overlap, the non-specificity of the symptoms, and the often 
limited ability to determine the true etiology, hemophagocytic syndromes are defined on 
the basis of clinical findings (Henter et al., 2007). The criteria include many of the 
features noted by Scott and Robb-Smith, such as persistent fever and splenomegaly. 
Hepatomegaly and progressive hepatic dysfunction, leading to jaundice and the purpuric 
rash they described, is also common, as is lymphadenopathy and coagulopathy. 
Neurologic involvement occurs in about a quarter of cases. Laboratory abnormalities are 
remarkable for hyperferritinemia, cytopenias affecting multiple blood cell lineages 
(anemia, leukopenia, and/or thrombocytopenia), high soluble CD25 (the IL-2 receptor), 
and elevated levels of multiple cytokines. Histologic criteria are unchanged from those 
noted over 80 years ago: a marked lymphohistiocytic infiltrate into the bone marrow, 
liver, spleen, or other organs, and the frequent presence of hemophagocytes. However, 
the latter is no longer considered to be pathognomonic for hemophagocytic syndrome, 
as hemophagocytosis is neither a sensitive nor specific indicator of these diseases (Goel 
et al., 2012; Gupta et al., 2008).  
While Scott and Robb-Smith did not speculate into the mechanisms responsible 
for these clinical findings, much progress has been made into understanding how these 
symptoms arise. We now know that this constellation of seemingly disparate, non-
specific symptoms are ultimately manifestations of unbridled inflammation and represent 
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the final common pathway of systemic immune activation (Canna and Behrens, 2012). 
The “cytokine storm” is thought to play a central role in driving pathology. Pyrogens such 
as IL-1β, IL-6, and TNFα drive fever through their effects on the hypothalamus (Janka, 
2007); these cytokines also suppress hematopoiesis, leading to decreased output of 
erythrocytes, leukocytes, and platelets (Brisse et al., 2016). IFNγ in particular promotes 
anemia (Canna et al., 2013), but also skews lymphocyte production, leading to a 
profound B lymphopenia (Baratono et al., 2015). Disseminated intravascular coagulation 
(DIC) may also contribute to anemia through hemolysis, and to thrombocytopenia 
through platelet consumption (Brisse et al., 2016). IFN-I and TNFα mediate cachexia. IL-
1β stimulates macrophages to release plasminogen activator, which promotes 
fibrinolysis and thus DIC (Rosado and Kim, 2013). TNFα induces release of ferritin by 
activated macrophages (Sieni et al., 2014). Ferritin, in its non-glycosylated form, is also 
released by necrotic tissue (Brisse et al., 2016). TNFα also stimulates triglyceride 
synthesis while inhibiting lipoprotein lipase, leading to hypertriglyceridemia, 
microvesicular steatosis, and hepatocyte dysfunction (Henter et al., 1991). TNFα and IL-
1β increase vascular permeability, leading to fluid leakage into the tissues and reduction 
in intravascular volume, which, along with the embolic effects of DIC, contributes to 
hypoperfusion (Sieni et al., 2014). Activation of macrophages leads to the excessive 
release of cytokines such as IL-1β, IL-6, and IL-12, which activate T lymphocytes to 
proliferate and produce IFNγ, which further heightens macrophage activation (Rosado 
and Kim, 2013). Accumulation of both activated macrophages and lymphocytes in 
tissues promotes organ dysfunction – such as liver dysfunction, which exacerbates the 
bleeding diathesis by reducing production of clotting factors and fibrinogen (Brisse et al., 
2016). Hypoperfusion, DIC, and organ infiltration by inflammatory cells lead to cell death 
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and the further release of DAMPs and inflammatory mediators. Cumulatively, this leads 
to tissue destruction and multi-organ dysfunction. In the absence of intervention, these 
pathologic processes compound and rapidly overwhelm the body’s ability to 
compensate. Thus, the pathophysiology of hemophagocytic syndrome is driven by 
positive feedback among multiple inflammatory circuits, which eventually overwhelms 
normal regulatory mechanisms to cause self-perpetuating inflammation (Canna and 
Behrens, 2012). The collateral damage suffered by normal bystander cells and tissues – 
so-called immunopathology – is the inadvertent result that ultimately risks the survival of 
the organism.  
Therefore, hemophagocytic syndrome is a life-threatening disease, and the 
prognosis of patients is quite poor. For primary hemophagocytic syndrome, overall three-
year survival is only about 50%, even with optimal treatment, which includes a regimen 
of high-dose dexamethasone, etoposide, and cyclosporine, followed by hematopoietic 
stem cell transplantation for definitive cure (Henter et al., 2007; Rosado and Kim, 2013). 
Mortality rates in secondary forms are more variable, ranging from 20-85%, depending 
on the underlying cause (Brisse et al., 2016). Outcomes have improved in recent 
decades, owing much to advances in supportive care and increased recognition of the 
disease (Créput et al., 2008; Meeths et al., 2014). However, effective targeted therapies 
remain a significant unmet clinical need in the treatment of hemophagocytic syndromes. 
Consequently, greater insight into the underlying pathophysiology of these diseases is 
vitally necessary. 
 
The role of CD8+ T cells in hemophagocytic syndromes 
 Lymphocytes and histiocytes have been recognized as a key component of 
hemophagocytic syndromes since Scott and Robb-Smith’s original histologic 
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descriptions. However, the mechanism responsible for their activation and infiltration into 
tissues had remained more mysterious until relatively recently. Much of our 
understanding of hemophagocytic syndrome pathophysiology is based on studies of the 
familial form of hemophagocytic lymphohistiocytosis, FHL. The occurrence of the 
disease in family cohorts, coupled with its presentation at an early age – frequently 
during the first year of life – were highly suggestive of a genetic basis for this disease. A 
major clue came with the identification of defects in the cytotoxic function of CD8+ T cells 
and natural killer (NK) cells in patients with hemophagocytic syndrome (Egeler et al., 
1996; Sullivan et al., 1998). In 1999, Stepp and colleagues subsequently reported that 
mutations in PRF1, the gene encoding the cytotoxic effector molecule perforin, was the 
genetic lesion responsible for FHL (now designated FHL type 2, or FHL2) (Stepp et al., 
1999). In the years since, numerous other mutations have been identified, all affecting 
the granule exocytosis pathway. These include mutations in MUNC 13-4 (Unc13D) in 
FHL3; syntaxin-11 (STX11) in FHL4; and MUNC 18-2 (STXBP2) in FHL5 (Côte et al., 
2009; Feldmann et al., 2003; zur Stadt et al., 2009; zur Stadt et al., 2005). 
Consequently, CD8+ T cells and NK cells from patients with FHL3, FHL4, or FHL5 
demonstrate defects in degranulation, as evidenced by reduced mobilization of granule-
associated CD107a to the plasma membrane; and these cells exhibit diminished target 
cell lysis in all forms of the disease. 
Such an immune deficit, restricted to the specialized function of CD8+ T cells and 
NK cells, clearly implicates these cells in FHL pathophysiology. The fact that viral 
infections commonly trigger FHL is consistent with a role for these cytotoxic cells in 
contributing to the disease (Brisse et al., 2014). Furthermore, mounting evidence 
suggests that dysregulated CD8+ T cells are a prominent feature common to many forms 
of hemophagocytic syndrome. Despite the lack of identifiable genetic mutations in 
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perforin or other granule exocytosis-associated genes, diminished CD8+ T cell and NK 
cell cytotoxicity is a common finding in MAS and other forms of hemophagocytic 
syndrome (Grom et al., 2003). Many forms of the disease, including MAS and EBV-
induced hemophagocytic lymphohistiocytosis, are triggered by viral infections and 
feature high serum levels of IFNγ, a major effector cytokine of CD8+ T cells (Schulert and 
Grom, 2014). Elevated sCD25, indicative of T cell activation, is also prominent in 
hemophagocytic syndromes and constitutes a diagnostic criterion (Brisse et al., 2016). 
Finally, effective treatments for hemophagocytic syndromes include anti-T cell therapies, 
such as cyclosporine and anti-thymocyte globulin (Henter et al., 2007). Thus, aberrant 
CD8+ T cell activity is highly implicated in hemophagocytic syndromes. 
 
Dissertation structure 
This thesis examines the role of CD8+ T cells in the context of hemophagocytic 
syndromes, with particular attention to their interaction with the surrounding cytokine 
storm. A central theme throughout the following studies is the role of antigen-
independent signals – whether DAMPs or PAMPs – to enhance the activation of CD8+ T 
cells and influence their cytokine production properties. The overarching goal of this 
work is to provide greater resolution into the key features of hemophagocytic syndromes 
and the mechanisms of immune dysregulation that drive them, in order to inform the 
future development of specific immunotherapies. In trying to better understand how 
dysregulation of CD8+ T cells tips the balance from productive immunity to damaging 
immunopathology, we may endeavor to dissect the dysregulated networks that underlie 
disorders of systemic hyperinflammation. 
In Chapter 2, we use a murine model of FHL2 to investigate the role of MyD88-
dependent signals in the development of FHL and ultimately find that the IL-33/ST2 axis 
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is a crucial amplifier of immune-mediated disease. We further explore the mechanism 
underlying the role of ST2 in FHL2 in Chapter 3 and demonstrate that ST2 intrinsically 
promotes proliferation of pathogenic effector CD8+ and CD4+ T cells and their 
overproduction of IFNγ. In Chapter 4, we examine the protective effects of long-term ST2 
blockade in murine FHL2, finding that disruption of ST2 signaling reduces chronic 
wasting in part by enabling exhaustion of CD8+ T cells. Turning to a different model of 
hemophagocytic syndrome in Chapter 5, we investigate a novel subset of effector-like 
CD8+ T cells that are associated with liver damage in the murine model of MAS. Finally, 
in Chapter 6, we review remaining questions, suggest future lines of investigation, and 
discuss the implications of these findings on hemophagocytic syndromes and other 
systemic inflammatory diseases. 
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CHAPTER 2: 
ST2 promotes fatal hemophagocytic lymphohistiocytosis in mice 
 
Introduction 
Hemophagocytic syndromes are life-threatening, cytokine-driven disorders 
associated with a wide range of disease states and increasingly recognized as a 
significant clinical problem. The primary form of hemophagocytic syndrome, known as 
familial hemophagocytic lymphohistiocytosis, is caused by genetic defects in perforin 
(FHL type 2, or FHL2) or other proteins in the granule exocytosis pathway (Brisse et al., 
2014; Stepp et al., 1999). Due to the absence of immune-mediated cytotoxicity in FHL, 
viral infections and other inflammatory stimuli trigger an ineffective yet hyperactive 
immune response leading to fatal immunopathology (Schmid et al., 2010). Advances in 
supportive care and hematopoietic stem cell transplantation (HSCT) over the past few 
decades have greatly improved the prognosis of patients with hemophagocytic 
syndrome (Horne et al., 2005). However, the non-specific immunosuppressive treatment 
regimen required to bridge FHL patients to transplant or induce remission in cases of 
secondary hemophagocytic syndrome have significant adverse effects and are 
sometimes ineffective; as a result, three-year survival for FHL patients receiving the 
standard of care is about 50% (Rosado and Kim, 2013). Ultimately, the difficulty in 
treating FHL and related hemophagocytic syndromes stems from a paucity of specific 
immunotherapies and incomplete understanding of the underlying pathophysiology.  
 The well-defined genetic basis for FHL2 has led to the development of a murine 
model using perforin-deficient (Prf1-/-) mice. As is true of humans deficient in perforin, 
Prf1-/- mice develop hemophagocytic syndrome when triggered by a viral infection, in this 
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case lymphocytic choriomeningitis virus (LCMV). Perforin deficiency renders CD8+ T 
cells and NK cells incapable of lysing target cells; however, without death of the target 
cell, virus-specific CD8+ T cells fail to disengage from their targets (Jenkins et al., 2015). 
This results in prolonged duration of immunological synapse formation, repetitive 
intracellular calcium flux, and hypersecretion of IFNγ and other pro-inflammatory 
cytokines. Reduced clearance of viral antigen further promotes CD8+ T cell activation 
and proliferation (Lykens et al., 2011; Terrell and Jordan, 2013). These FHL2 mice thus 
develop lethal inflammation driven by overabundant IFNγ-producing LCMV-specific CD8+ 
T cells (Jordan et al., 2004; Lykens et al., 2011; Matloubian et al., 1999). 
Prior studies attribute this hyperactive T cell response to excessive antigen 
stimulation through the TCR (Terrell and Jordan, 2013), due to their inability to eliminate 
APCs (Chen et al., 2011). While this mechanism accounts for part of the disease 
phenotype, it fails to explain why persistent antigen in the context of infection is not 
always sufficient to induce FHL in both murine models and patients. Of the numerous 
viruses tested in Prf1-/- mice, only LCMV and murine cytomegalovirus are documented to 
cause hemophagocytic syndrome (Brisse et al., 2014). Moreover, a portion of FHL 
patients present with hemophagocytic syndrome only later in childhood or adulthood, by 
which time they have certainly experienced multiple viral infections (Trizzino et al., 
2008). Together, these observations suggest that additional unidentified factors are 
required for the development of FHL.  
Given the importance of pathogen- and danger-associated molecular patterns in 
initiating inflammation, one previous study focused on the adaptor protein MyD88, which 
is required for signaling by IL-1 family cytokines and most TLRs. Using the murine model 
of FHL3, in which Unc13djinx/jinx mice are infected with LCMV, this study demonstrated 
that loss of MyD88 signaling confers protection from hemophagocytic syndrome (Krebs 
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et al., 2011). Unc13djinx/jinx/Myd88poc/poc mice developed LCMV-specific CD8+ T cell 
frequencies comparable to those of WT mice, suggesting that rather than limiting the 
ability of APCs to prime T cell responses, loss of MyD88 signaling abrogated a crucial 
pro-inflammatory signal (Krebs et al., 2011). These data demonstrate a requirement for 
additional MyD88-dependent, antigen-independent signals for disease induction, but it 
remains unclear which mediators upstream of MyD88 are responsible for promoting the 
development of FHL.  
In this study, we investigated the role of MyD88-dependent signaling pathways in 
precipitating disease in FHL2 mice, with a particular focus on the IL-1 receptor family 
member ST2 and its ligand, IL-33. IL-33 is a DAMP constitutively expressed in the nuclei 
of non-hematopoietic cells and is released upon cellular stress or necrosis (Cayrol and 
Girard, 2009; Kakkar et al., 2012; Luthi et al., 2009; Moussion et al., 2008; Pichery et al., 
2012). Once extracellular, IL-33 is able to bind ST2, expressed by a diverse range of 
immune cells, and thus induce inflammation in response to tissue damage (Liew et al., 
2010). We ultimately identify ST2 as a novel factor promoting FHL. Our data 
demonstrate that ST2 signaling enhances IFNγ hypercytokinemia, leading to fatal 
disease, and suggest IL-33/ST2 as a promising therapeutic target. Furthermore, our 
work provides evidence for revising the traditional model of FHL pathophysiology to take 
into account danger signals derived from tissue damage.   
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Results 
MyD88 is required for the development of FHL2 in mice 
MyD88 is necessary for disease in the murine model of FHL3 (Krebs et al., 
2011). To determine whether MyD88 signaling contributes to FHL2, we compared the 
response of Prf1-/- and Prf1-/-Myd88-/- mice to LCMV infection. Prf1-/- mice became 
moribund by day 10 post-infection (p.i.), while Prf1-/-Myd88-/- mice did not (data not 
shown). MyD88 deficiency protected Prf1-/- mice from multiple facets of disease, 
including splenomegaly, anemia, and thrombocytopenia (Figure 2.1A-B). Hepatitis was 
also markedly reduced in Prf1-/-Myd88-/- mice, as these mice demonstrated considerably 
fewer lobular foci of inflammatory infiltrates compared to Prf1-/- controls (Figure 2.1C). 
Consistent with their reduced FHL severity, Prf1-/-Myd88-/- mice had decreased levels of 
serum IFNγ and frequencies of CD8+ T cells specific for the immunodominant LCMV 
epitope gp33 compared to Prf1-/- mice (Figure 2.1D-E). These results suggest that non-
TCR signaling pathways such as MyD88 are important for promoting disease in the 
FHL2 murine model, similar to findings in the FHL3 model. 
 
Splenic expression of IL-33 is enhanced in FHL2 mice, and expression of ST2 is 
increased in both mice and patients with FHL2 
To delineate the signaling mediators upstream of MyD88 that contribute to the 
development of FHL, we focused on signaling through IL-1 family receptors. While in 
vivo blockade of either IL-1 or IL-18 signaling has no effect on FHL mortality (Jordan et 
al., 2004; Krebs et al., 2011), the role of IL-33 signaling in FHL has not previously been 
investigated. Recent studies have shown that ST2 deficiency in LCMV-infected mice 
leads to defective expansion and polyfunctionality of LCMV-specific CD8+ and CD4+ T 
cells, as well as protection from mortality in a CD8+ T cell-mediated model of 
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immunopathology (Baumann et al., 2015; Bonilla et al., 2012). These findings led us to 
hypothesize that ST2 signaling upstream of MyD88 contributes to FHL inflammation.  
We first determined whether IL-33 and ST2 are expressed in the organs most 
affected by FHL in LCMV-infected Prf1-/- mice (referred to as FHL2 mice). While hepatic 
expression of Il33 remained stable in both WT and Prf1-/- mice following LCMV infection, 
splenic Il33 was greatly upregulated (Figure 2.2A). Notably, Il33 expression was highest 
in the spleens of FHL2 mice. Immunohistochemical analysis confirmed nuclear 
localization of IL-33 in WT and Prf1-/- livers and spleens (Figure 2.2B and data not 
shown). Although the spatial distribution and number of IL-33+ cells did not change 
substantially after infection, IL-33-expressing cells in LCMV-infected tissue exhibited 
larger, rounder nuclei, consistent with a more activated status (Figure 2.2B and data not 
shown).  
Expression of ST2 (encoded by Il1rl1) was greatly increased in spleens and 
livers of FHL2 mice compared to LCMV-infected WT mice (Figure 2.2C), indicating either 
upregulation of ST2 on immune cells or an influx of ST2-expressing cells into these 
tissues. To determine whether similar changes were also evident in perforin-deficient 
patients, we examined ST2 expression in peripheral blood mononuclear cells (PBMC) 
from human FHL2 patients, using public data sets (Hinze et al., 2010; Sumegi et al., 
2011). Expression of ST2 was highly upregulated in pediatric FHL2 patients compared to 
healthy children and children with an unrelated inflammatory disease (systemic juvenile 
idiopathic arthritis) (Figure 2.2D). Together, these results show that IL-33 and ST2 are 
highly expressed in both mice and humans with FHL2, warranting further investigation of 
a potential role for the IL-33/ST2 pathway in driving disease. 
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Blockade of ST2 reduces mortality and morbidity, including hepatitis and liver 
damage, in FHL2 mice 
To explore the impact of the IL-33/ST2 pathway on disease, we disrupted IL-33 
signaling in FHL2 mice by administration of ST2-blocking antibody (α-ST2). Remarkably, 
α-ST2-treated mice were significantly protected from mortality and weight loss compared 
to FHL2 mice receiving isotype control antibody (Control) (Figures 2.3A-B). Continual 
ST2 blockade promoted survival at least 30 days p.i. and limited chronic weight loss 
compared to mice withdrawn from α-ST2 treatment (Figure 2.3C). Additionally, α-ST2-
treated mice showed less severe thrombocytopenia and anemia compared to Controls 
(Figures 2.3D-E). Disease activity markers such as ferritin and soluble CD25 were also 
decreased upon ST2 blockade (Figures 2.3F-G). Spleen size and cellularity did not differ 
markedly between Control and α-ST2 treated mice, with both groups showing expanded 
white pulp and extramedullary hematopoiesis (Figures 2.3H-I and data not shown). 
However, ST2 blockade significantly reduced hepatomegaly and total numbers of 
intrahepatic leukocytes compared to Control mice, despite similar numbers of lobular 
inflammatory foci (Figure 2.4A-C). Numbers of CD8+ and CD4+ T cells were diminished 
in the livers of α-ST2-treated mice, suggesting a particular dependence on IL-33 
signaling by cells known to be hyperactivated in FHL2 mice (Figures 2.4D-E). 
Furthermore, liver parenchymal damage in the form of microvesicular steatosis was 
greatly decreased in α-ST2-treated mice relative to Controls (Figure 2.4F), indicating 
protection from the severe, acute metabolic disturbances typical of hypoxia (Jaeschke et 
al., 2002). Together, these data show that the severity of FHL is significantly reduced by 
ST2 blockade. 
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ST2 blockade suppresses the immune response rather than LCMV infection 
To determine whether the improved outcome of FHL2 mice receiving ST2 
blockade was due to enhanced control of viral replication, we measured splenic LCMV 
titers 8 days p.i. Despite their ameliorated disease, α-ST2-treated FHL2 mice were no 
better able to clear LCMV than Control FHL2 mice, whereas LCMV-infected WT mice 
receiving either treatment cleared the infection easily (Figure 2.5A). These results 
suggest that rather than modulating resistance to the pathogen, ST2 signaling modifies 
the pathologic immune response. 
A critical requirement for immunopathology in FHL is IFNγ, whose serum levels 
correlate with disease severity (Jessen et al., 2013; Jordan et al., 2004). IL-33 promotes 
T cell effector function and synergizes with IL-12 to induce IFNγ production by T cells 
and NK cells (Baumann et al., 2015; Bonilla et al., 2012; Bourgeois et al., 2009; Yang et 
al., 2011); thus, we hypothesized that ST2 blockade reduces disease severity in FHL2 
mice by diminishing systemic levels of IFNγ. α-ST2 treatment significantly decreased 
serum IFNγ in LCMV-infected WT mice, but mediated a more striking 16-fold reduction in 
FHL2 mice (Figure 2.5B). These data demonstrate that the vast majority of pathogenic 
IFNγ is under the control of ST2 signaling and underscore the central role of IL-33 in 
amplifying inflammation in FHL.  
 
Not all DAMPs promote FHL disease in mice 
 These data demonstrate that danger signals associated with tissue damage, 
such as IL-33, are capable of augmenting immune dysregulation in this disease. 
Whether IL-33 is unique among DAMPs in this role remains unclear. Therefore we 
tested whether high mobility group protein B1 (HMGB1), a ubiquitously expressed 
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DAMP, plays an analogous role in murine FHL (Scaffidi et al., 2002). Similar to IL-33, 
HMGB1 is a nuclear protein released by cellular necrosis, although it can also be 
secreted by activated macrophages (Degryse et al., 2001; Harris et al., 2012). HMGB1 
induces cytokine production, proliferation, and migration through interactions with 
receptor of advanced glycation end products (RAGE), as well as TLR2, TLR4, and 
TLR9. Given the MyD88-dependent nature of FHL (Figure 2.1) and the ability of HMGB1 
to interact with TLRs upstream of MyD88, we hypothesized that HMGB1 would also 
contribute to inflammation in this model. However, administration of neutralizing antibody 
against HMGB1 failed to rescue FHL2 mice from mortality, weight loss, 
thrombocytopenia, or anemia (Figure 2.6A-D). Consistent with this lack of impact on 
disease severity, serum levels of IFNγ were unaltered by HMGB1 neutralization (Figure 
2.6E). Thus, not all DAMPs are capable of promoting inflammation in murine FHL. While 
these data do not exclude a potential contributory role for other DAMPs in FHL, they 
suggest that IL-33 may be uniquely pathogenic in this disease. 
 
The pathogenic role of ST2 signaling in FHL2 mice is not a feature of all murine 
models of hemophagocytic syndrome 
 Given the importance of IL-33 to FHL pathophysiology, and the high degree of 
tissue damage common to hemophagocytic syndromes, we next investigated whether 
ST2 blockade would be protective in another murine model of hemophagocytic 
syndrome. We used the TLR9-induced model of macrophage activation syndrome 
(TLR9-MAS), in which serial injections of the TLR9 ligand, CpG, into wild-type mice 
triggers a hyperinflammatory syndrome characterized by cytopenias, 
hepatosplenomegaly, hepatitis, and hypercytokinemia. Similar to the murine model of 
FHL2, disease in TLR9-MAS mice is highly dependent on elevated levels of IFNγ; 
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however, neither genetic susceptibility nor live infection is required (Behrens et al., 
2011). In contrast to the protective effect of ST2 blockade in FHL2 mice, ST2 blockade 
in TLR9-MAS mice had no effect on disease markers such as thrombocytopenia or 
anemia (Figure 2.7A-B); splenomegaly was likewise unchanged  (Figure 2.7C). Unlike 
FHL2 mice, loss of ST2 signaling in TLR9-MAS mice did not impact hepatomegaly or the 
number or composition of the hepatic inflammatory infiltrate (Figure 2.7D-E and data not 
shown). Consistent with these findings, systemic levels of IFNγ were unaltered by ST2 
blockade (Figure 2.7F). These data demonstrate that disease in TLR9-MAS mice occurs 
independently of ST2, suggesting that IL-33 may not be required for the development of 
all forms of hemophagocytic syndrome. Thus, the pathogenic role of ST2 signaling in 
LCMV-infected Prf1-/- mice may represent a particular feature of FHL pathophysiology.  
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Discussion 
This study reveals a previously undescribed role for ST2 in FHL pathophysiology. 
Expression of both IL-33 and ST2 is increased in tissues of FHL2 mice, and ST2 is 
similarly upregulated in human FHL2 patients. Danger signals provided by IL-33 
enhance morbidity and mortality in murine FHL2 by intensifying overproduction of IFNγ, 
independent of viral load. Notably, these pathogenic effects are not elicited by a similar 
DAMP in FHL2 mice, nor by ST2 in a related model of hemophagocytic syndrome, 
suggesting the relationship between IL-33/ST2 and FHL may be unique. 
Our data demonstrate that adjuvant-like TCR-independent signals critically 
contribute to the hyperinflammation of FHL. While excessive antigen is certainly 
necessary for the development of disease, it may not be sufficient. This study suggests 
that inflammatory cytokines, such as IL-33, are required to amplify the immune response 
such that it exceeds the threshold of protective inflammation and becomes pathogenic.  
More broadly, the fact that IL-33 is released by necrotic cells implies that tissue damage 
is a cause of immune dysregulation, rather than a consequence. 
Disruption of either MyD88 or ST2 signaling in FHL2 mice dramatically 
ameliorates disease, with reductions in cytopenias, hepatitis, serum IFNγ, and LCMV-
specific CD8+ T cells. Since ST2 is upstream of MyD88, these results suggest that many 
of the improvements effected by MyD88 deficiency in this model are due to loss of IL-33 
signaling. However, our data also show that disruption of ST2 does not phenocopy 
MyD88 deficiency in FHL2 mice, since certain disease markers such as splenomegaly 
and hepatic lobular inflammation are unchanged by ST2 blockade. Thus, while IL-33 is a 
major MyD88-dependent inflammatory amplifier, it is possible that additional signaling 
mediators upstream of MyD88, such as other IL-1 family receptors and TLRs, also 
contribute. For example, neutralization of IL-18 mitigates organ damage in FHL2 mice 
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despite its inability to reduce mortality (Chiossone et al., 2012; Jordan et al., 2004). 
Deficiency of IL-1R, TLR7, or TLR9 fails to restrict expansion of LCMV-specific CD8+ T 
cells (Jung et al., 2008; Krebs et al., 2011), but a role for these pathways in combination 
with more dominant signals such as ST2 has not been investigated.  
Based on the decisive role that the IL-33/ST2 pathway plays in FHL2, we were 
surprised to find that blockade of HMGB1, a DAMP with many similarities to IL-33, had 
no impact on disease in this model. This may be due to the fact that HMGB1 likely 
possesses little intrinsic immunostimulatory capacity, and instead complexes with other 
molecules to induce immune responses (Pisetsky et al., 2008). Alternatively, this may 
support the specificity of IL-33 in promoting inflammation in the FHL2 model. It is 
possible that HMGB1 could act in a manner similar to IL-33 in the context of a different 
model of hemophagocytic syndrome, depending on the key cell types and immune 
networks responsible for that disease. Consistent with this idea, we demonstrated that 
IL-33 is not universally pathogenic in systemic inflammatory disease, since ST2 
blockade failed to alter the severity of TLR9-MAS. Further investigation may determine 
whether the requirement of DAMPs for fulminant disease constitutes a cardinal feature 
of all hemophagocytic syndromes, or whether this represents a particular aspect of FHL2 
pathophysiology. 
This pathogenic IL-33/IFNγ axis may provide an important point of manipulation 
for the treatment of FHL, particularly since ST2 expression is elevated in PBMC from 
FHL2 patients (Figure 2.2D). While numerous cytokines have been experimentally 
modulated in FHL mice, IFNγ and now IL-33/ST2 are the only immune mediators whose 
blockade demonstrates therapeutic benefit (Jordan et al., 2004; Krebs et al., 2011). 
Disruption of ST2 signaling reduces systemic IFNγ to sub-lethal levels without rendering 
FHL2 mice completely deficient in this key antiviral cytokine; accordingly, viral control is 
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not worsened in these mice (Figure 2.5). Targeting IL-33/ST2 is therefore potentially 
safer than targeting IFNγ directly, as patients with disrupted IFNγ signaling show 
increased susceptibility to infection, and genetic deletion of the IFNγ receptor in FHL3 
mice enhances mortality (Browne and Holland, 2010; Dorman and Holland, 2000; Krebs 
et al., 2011). Furthermore, recently described cases of FHL occurring in patients with 
IFNγ receptor deficiency highlight the need for therapeutics designed to target a diverse 
range of pathways in FHL (Tesi et al., 2015). Our study demonstrates that ST2 blockade 
is protective in FHL2 mice after infection, but before the development of overt disease. 
Thus, it is unclear whether the optimal use of ST2 blockade would be for treatment of 
flare versus prophylaxis, and any future study in human disease might need to consider 
both possibilities. 
In summary, we have demonstrated that disruption of ST2 signaling in the murine 
model of FHL reduces systemic levels of IFNγ, leading to improved morbidity and 
mortality, and suggest blockade of this pathway as a viable treatment strategy for FHL. 
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Figures 
 
Figure 2.1. MyD88 is required for the development of FHL2 in mice. 
Prf1-/- (n=3) and Prf1-/-Myd88-/- (n=3) mice were infected with LCMV and analyzed 10 
days p.i. for signs of FHL2. Representative of 3 independent experiments performed by 
Sheila Rao. Analyzed by Student’s two-tailed t-test. (A) Spleen weight expressed as a 
ratio of total body weight. (B) Platelet and hemoglobin levels from peripheral blood. (C) 
Representative H&E-stained liver sections, original magnification ×100. Staining and 
analysis performed by Portia Kreiger. (D) Serum IFNγ levels. (E) Frequencies of splenic 
LCMV-specific CD8+ T cells stained with gp33 MHC Class I tetramer. 
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Figure 2.2. Splenic expression of IL-33 is enhanced in FHL2 mice, and expression 
of ST2 is increased in both mice and patients with FHL2. 
Spleens and livers from Prf1-/- and WT mice were analyzed before and after LCMV 
infection. (A) Expression of Il33 at days 0 (Uninf) and 7 p.i. (Inf) (n=4 mice/group). AU, 
arbitrary units. Analyzed by two-way ANOVA. Significance of terms is denoted as 
follows: #, Genotype (WT vs. Prf1-/-); ‡, LCMV (Uninf vs. Inf); *, Interaction between 
Genotype and LCMV. (B) Immunohistochemical staining of IL-33 in Prf1-/- mice, original 
magnification ×200. Representative of 4 mice/group. Staining was performed by Joanne 
Mauger and slides were analyzed by Michele Paessler. (C) Expression of Il1rl1 (ST2 
gene), analyzed as in (A). (D) Expression of IL1RL1 in PBMC from pediatric patients 
with FHL2 (n=3), patients with systemic juvenile idiopathic arthritis (sJIA, n=18), and 
healthy controls (Control 1, n=33; Control 2, n=29). Data are combined from two 
published data sets (GSE26050, shown in triangles; and GSE21521, shown in 
diamonds) and processed to remove batch effects (Johnson et al., 2007). Analyzed by 
one-way ANOVA; significance of Dunnett’s multiple comparison post-test comparing 
FHL2 patients to all other groups is indicated. 
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Figure 2.3. ST2 blockade reduces morbidity and mortality of FHL2 mice.  
Prf1-/- mice were infected with LCMV to induce FHL2 and treated with 150 µg of either α-
ST2 or Control antibodies every other day, beginning on day 3 p.i. (A) Survival of α-ST2-
treated (n=9) and Control (n=10) mice. Representative of 2 independent experiments. 
Analyzed by log-rank (Mantel-Cox) test. LCMV-infected WT mice (n=4) are included for 
visual comparison. (B) Body weight of α-ST2-treated and Control mice. Symbols 
represent mean ± SEM of 9-10 mice. † indicates timepoints at which Control mice died 
and were excluded from subsequent weight analysis. Representative of 2 independent 
experiments. Analyzed by linear mixed-effects model to allow for missing data due to 
mouse mortality: treatment and body weight were modeled as fixed effects, and 
individual mice were treated as a random effect to account for baseline variability 
between animals (e.g. intercept only). Significance of Interaction term (α-ST2 vs. Control 
over time) is indicated. LCMV-infected WT mice (n=4) are included for visual 
comparison. (C) Body weight of Prf1-/- mice withdrawn from α-ST2 treatment and 
switched to Control antibody at day 18 p.i. (w/d, withdrawal) or receiving continued α-
ST2 treatment. Symbols represent mean ± SEM of 4-5 mice. † indicates timepoint at 
which 1 Withdrawal mouse died and was excluded from subsequent weight analysis. 
Analyzed by linear mixed-effects model as in (B); significance of Interaction term (α-ST2 
vs. Withdrawal over time) is indicated. (D) Platelet and (E) hemoglobin levels from 
peripheral blood of α-ST2-treated (n=9) and Control (n=10) Prf1-/- mice 2 days prior to 
infection and 8 days p.i. Representative of 2 independent experiments. Analyzed by 
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repeated-measures two-way ANOVA; significance of Interaction term (α-ST2 vs. Control 
over time) is indicated. (F) Ferritin and (G) sCD25 levels in serum. N=7-8 mice/group, 
data pooled from 2 independent experiments. (H) Spleen weight, indexed to total body 
weight, and (I) total numbers of splenocytes. N=4 mice/group, representative of 2 
independent experiments. (F-I) Samples taken 8 days p.i. and analyzed by Student’s 
two-tailed t-test. 
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Figure 2.4. ST2 blockade improves hepatitis and liver damage in FHL2 mice.  
Liver pathology in α-ST2-treated (n=4) and Control (n=4) Prf1-/- mice 8 days p.i. 
Representative of 2 independent experiments. Analyzed by Student’s two-tailed t-test. 
(A) Liver weight, expressed as a ratio of total body weight. (B) Total numbers of 
intrahepatic leukocytes. (C) Numbers of lobular inflammatory foci per 20X objective high-
power field (hpf), enumerated from H&E-stained tissue sections. (D-E) Total numbers of 
intrahepatic CD8+ T cells (D) and CD4+ T cells (E), as measured by flow cytometry. (F) 
Representative H&E-stained liver sections, original magnification ×200. Severity of 
microvesicular steatosis was assessed on day 8 p.i. using a standardized scoring 
system as follows: 0 – absent, 1 – 1-20% of area per 20X objective hpf, 2 – 21-40%, 3 – 
41-60%, 4 – 61-80%, 5 – 81-100%. In (C) and (F), H&E staining was performed by the 
Pathology Core Laboratory at CHOP and slides were scored by Portia Kreiger. 
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Figure 2.5. ST2 blockade suppresses the immune response rather than LCMV 
infection. 
WT and Prf1-/- mice were infected with LCMV, treated with either α-ST2 or Control 
antibodies on days 3, 5, and 7 p.i., and analyzed on day 8 p.i. N=4 mice/group. Analyzed 
by two-way ANOVA. Significance of terms is denoted as follows: #, Genotype (WT vs. 
Prf1-/-); §, Treatment (Control vs. α-ST2); *, Interaction between Genotype and 
Treatment. (A) Splenic LCMV titer. Dotted line indicates limit of detection of plaque 
assay. Representative of 2 independent experiments. (B) Serum IFNγ level. 
Representative of 3 independent experiments.  
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Figure 2.6. Not all DAMPs promote FHL disease in mice. 
Prf1-/- mice were infected with LCMV to induce FHL2 and treated with 50 µg of either α-
HMGB1 antibody (n=4 mice) or Control antibody (n=5 mice) every 3 days, beginning on 
day 3 p.i. (A) Survival of α-HMGB1-treated and Control mice. Not significant by log-rank 
(Mantel-Cox) test. (B) Body weight of α-HMGB1-treated and Control mice. Symbols 
represent mean ± SEM of 4-5 mice. Analyzed by linear mixed- effects model as in Figure 
2.3B; interaction term (α-HMGB1 vs. Control over time) was not significant. (C) Platelet 
and (D) hemoglobin levels from peripheral blood of α-HMGB1-treated and Control mice 
2 days prior to infection and 8 days p.i. No significant interaction by repeated-measures 
two-way ANOVA. (E) Serum IFNγ level 8 days p.i. Not significant by Student’s two-tailed 
t-test. 
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Figure 2.7. The pathogenic role of ST2 signaling in FHL2 mice is not a feature of 
all murine models of hemophagocytic syndrome. 
C57BL/6 mice received 50 µg of CpG on days 0, 2, 4, 7, and 9 to induce TLR9-MAS and 
were concurrently treated with 150 µg of either α-ST2 or Control antibody (n=5 
mice/group) on days 2, 4, 7, and 9. Mice were euthanized and analyzed on day 10. (A) 
Platelet and (B) hemoglobin levels from peripheral blood of α-ST2-treated and Control 
TLR9-MAS mice 1 day prior to and 10 days after the first CpG dose. No significant 
interaction by repeated-measures two-way ANOVA. (C) Spleen weight and (D) liver 
weight, each expressed as a ratio of total body weight. (E) Total numbers of intrahepatic 
leukocytes. (F) Serum IFNγ level. (C-F) No significant differences by Student’s two-tailed 
t-test. 
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CHAPTER 3: 
Disruption of ST2 signaling limits expansion and IFNγ  production by 
pathogenic T cells in FHL2 mice 
 
Introduction 
 We have shown thus far that ST2 signaling amplifies the pathogenic immune 
response in murine FHL, leading to lethal levels of IFNγ. However, the mechanism 
underlying this enhanced immune response has not been elucidated. In this chapter, we 
will investigate the cellular sources of IFNγ that are responsive to IL-33 and dissect the 
impact of ST2 blockade on these populations. 
In FHL2 mice, serum IFNγ levels are significantly reduced by antibody-mediated 
CD8α depletion, and B2m-/- mice demonstrate similarly low serum IFNγ in response to 
LCMV infection, suggesting that the majority of IFNγ in this model derives from CD8+ T 
cells (Jordan et al., 2004). However, IFNγ levels in these mice remain elevated above 
that of WT mice, indicating that other cellular sources of IFNγ may contribute to the 
systemic pool. Indeed, IFNγ-producing CD4+ T cells are also expanded in FHL2 mice, 
although they remain far outnumbered by IFNγ+ CD8+ T cells (Lykens et al., 2011), and 
Rag2-/- mice show even lower serum IFNγ than B2m-/- mice after LCMV infection (Jordan 
et al., 2004). Prf1-/- NK cells also secrete excessive amounts of IFNγ when cultured in 
vitro with MC57 target cells (Jenkins et al., 2015). Thus, multiple types of IFNγ-producing 
lymphocytes may be targeted by IL-33/ST2 in FHL2 mice. 
Consistent with this hypothesis, IL-33 is capable of promoting the expansion 
and/or function of both T cells and NK cells in various contexts. ST2 is transiently 
expressed by a minority of CD8+ and CD4+ T cells during LCMV infection in vivo or when 
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cultured in vitro in Tc1/Th1-skewing conditions (Baumann et al., 2015; Bonilla et al., 
2012; Yang et al., 2011). This upregulation of ST2 is at least partially dependent on the 
key Tc1/Th1 lineage transcription factor T-bet, suggesting that acquisition of IL-33 
responsiveness may be a component of the normal effector T cell differentiation program 
(Baumann et al., 2015; Yang et al., 2011). Genetic ablation of ST2 intrinsically limits the 
accumulation of both CD8+ and CD4+ T cells specific for LCMV and reduces the 
expression of effector molecules such as IFNγ, TNFα, IL-2, and granzyme B during 
acute infection (Baumann et al., 2015; Bonilla et al., 2012). Conversely, exogenous 
administration of IL-33 enhances vaccine-elicited CD8+ T cell responses (Bonilla et al., 
2012; Villarreal et al., 2014). These findings highlight the ability of IL-33 signaling to 
promote the induction of acute effector CD8+ and CD4+ T cells in response to TCR 
stimulation. In addition, IL-33 shares the capability of its relative IL-18 to induce innate-
like IFNγ production in combination with a STAT activator. In the presence of IL-12, IL-33 
enhances antigen-independent IFNγ production by effector CD8+ T cells that have been 
recently activated by either LCMV in vivo or Tc1 differentiation conditions in vitro 
(Freeman et al., 2012; Yang et al., 2011). Similarly, IL-33 elicits IFNγ in an IL-12-
dependent manner from NK and invariant NKT cells directly ex vivo, in the absence of 
TCR or activating receptor ligands (Bourgeois et al., 2009).  
 Together, these studies demonstrate multiple potential mechanisms by which IL-
33 augments lymphocyte IFNγ production and lead us to hypothesize that the protective 
effect of ST2 blockade in FHL2 mice is mediated by direct limitation of IFNγ-producing T 
and NK cells, particularly CD8+ T cells. The finding that ST2-blocked FHL2 mice show 
lower serum levels of sCD25 (Figure 2.3G), a correlate of T cell activation, is consistent 
with this hypothesis. However, whether the effects of IL-33 on perforin-sufficient cells are 
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the same as on Prf1-/- cells, which intrinsically show dysregulated IFNγ production 
(Jenkins et al., 2015), remains unknown. Furthermore, it is unclear whether the ability of 
ST2 signaling to amplify IFNγ production in FHL2 mice is due to enhancement of the 
quantity or quality of IFNγ-producing cells.  
In this chapter, we find that ST2 intrinsically promotes the expansion of effector 
CD8+ and CD4+ T cells, leading to increased frequencies of LCMV-specific IFNγ-
producing T cells, but not NK cells, in FHL2 mice. Furthermore, ST2 signaling augments 
the quality of the effector T cell response by increasing per-cell production of IFNγ. Thus, 
ST2 directly amplifies both the quantity and quality of the pathologic T cell response in 
murine FHL to produce toxic levels of IFNγ that ultimately prove fatal. 
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Results 
Punctate IL-33 staining is consistent with lymphocyte responsiveness to IL-33 via 
ST2 
Based on our hypothesis that lymphocytes augment IFNγ production in response 
to IL-33, we expected to find lymphocytes in close proximity to IL-33-expressing cells in 
target organs of FHL2 mice. While foci of infiltrating lymphocytes were certainly adjacent 
to hepatic cells staining IL-33+ by immunohistochemistry (Figure 2.2B), we were 
intrigued to find that the lymphocytes themselves uniformly displayed punctate 
perinuclear IL-33 staining (Figure 3.1A). This would seem to contradict reports that IL-33 
is a nuclear factor not expressed in lymphocytes (Moussion et al., 2008; Pichery et al., 
2012). An identical IL-33-specific staining pattern was found in the sparser hepatic 
inflammatory infiltrates of LCMV-infected WT mice, as well (Figure 3.1B). However, in 
vivo blockade of ST2 eliminated this punctate staining without substantially diminishing 
the number of IL-33+ nuclei, suggesting that rather than endogenously expressing IL-33, 
lymphocytes internalize this cytokine in an ST2-dependent manner (Figure 3.1A). These 
data are consistent with receptor-mediated endocytosis of IL-33 and thus suggest that 
inflammatory lymphocytes in LCMV-infected mice respond to IL-33 via ST2. 
 
ST2 blockade decreases numbers of LCMV-specific effector CD8+ and CD4+ T cells 
in FHL2 mice 
To determine how lymphocytes respond to IL-33, we examined the abundance of 
lymphocytes in α-ST2-treated WT and FHL2 mice. ST2 blockade decreased the number 
of CD44hiCD62LloCD127lo effector CD8+ T cells in FHL2 mice (2.4-fold reduction), 
although not to the degree seen in LCMV-infected WT mice (5.4-fold reduction) (Figure 
3.2A-B). Effector CD4+ T cells were similarly reduced in number by α-ST2 treatment 
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(1.7- and 2.2-fold reductions in FHL2 and LCMV-infected WT mice, respectively) (Figure 
3.2C-D). Numbers of CD44hiCD62LhiCD127hi memory-phenotype cells were only slightly 
altered by α-ST2 treatment in FHL2 mice (1.2-fold reduction in CD8+ T cells) or not at all 
(1.01-fold increase in CD4+ T cells) (data not shown). Interestingly, numbers of NK cells 
were unaffected by ST2 blockade in either WT or FHL2 mice, suggesting that these cells 
likely contribute little to the IL-33-dependent IFNγ response (data not shown). Among 
effector-phenotype T cells, we found lower numbers of LCMV gp33-specific CD8+ T cells 
in α-ST2-treated FHL2 and LCMV-infected WT mice (Figure 3.2E-F). Although not 
statistically significant (P=0.054), there was a trend towards a greater α-ST2-mediated 
reduction of gp33-specific CD8+ T cells in LCMV-infected WT mice (5.9-fold) than in 
FHL2 mice (2.1-fold) (Figure 3.2F). Additionally, LCMV gp66-specific CD4+ T cells were 
reduced 3.5-fold by α-ST2 treatment in FHL2 mice (Figure 3.2G-H). Together, these 
findings suggest that ST2 promotes the expansion and/or differentiation of LCMV-
specific effector cells, which are known to be pathogenic in FHL2 mice. Furthermore, the 
suppressive effect mediated by ST2 blockade on effector CD4+ and CD8+ T cells differs 
in magnitude between LCMV-infected WT and FHL2 mice, highlighting the aberrations in 
T cell regulation characteristic of FHL.  
 
The frequency and IFNγ  production capacity of IFNγ+ LCMV-specific T cells are 
reduced in FHL2 mice receiving ST2 blockade 
We next investigated whether ST2 affects the ability of LCMV-specific effector 
cells to produce IFNγ. Control FHL2 mice demonstrated higher frequencies of IFNγ+ 
gp33-specific CD8+ T cells than Control LCMV-infected WT mice (Figure 3.3A-B), 
consistent with previous studies (Jordan et al., 2004; Lykens et al., 2011). Remarkably, 
40 
 
in vivo ST2 blockade reduced the frequency of IFNγ+ gp33-specific CD8+ T cells in FHL2 
and LCMV-infected WT mice to a similar degree (1.7- and 2.7-fold reductions, 
respectively) (Figure 3.3B). Likewise for CD4+ T cells, α-ST2 treatment decreased the 
frequency of IFNγ+ gp61-specific CD4+ T cells (2.7- and 2.2-fold reductions in FHL2 and 
LCMV-infected WT mice, respectively) (Figure 3.3C-D). Additionally, α-ST2 treatment 
reduced IFNγ median fluorescence intensity (MFI) in IFNγ+ LCMV-specific CD8+ and 
CD4+ T cells (Figure 3.3E-F), suggesting lower transcription or translation of this 
cytokine. Blockade of ST2 signaling therefore decreases both the frequency and 
average per-cell IFNγ production of IFNγ+ LCMV-specific T cells to cumulatively lower 
systemic IFNγ in FHL2 mice. 
 
Prf1-/-Il1rl1-/- mice resemble ST2-blocked Prf1-/- mice in pathologic and non-
pathologic states 
 To further investigate the role of IL-33/ST2 signaling in effector T cell induction, 
we crossed Prf1-/- mice to mice with a genetic disruption of Il1rl1, the gene encoding 
ST2, to generate mice deficient in both perforin and ST2 (Prf1-/-Il1rl1-/- mice). These mice 
were viable and showed no overt alterations in appearance or behavior. At baseline, 
normal frequencies and numbers of major immune cell populations were preserved 
(Figure 3.4A and data not shown). Additionally, frequencies of CD8+ and CD4+ T cells, 
as well as the frequencies of antigen-experienced (CD44+) cells within these subsets, 
were similar between Prf1-/- and Prf1-/-Il1rl1-/- mice (Figure 3.4B).  
To determine whether genetic deficiency of ST2 phenocopied the protective 
effects of α-ST2 antibody blockade, we infected Prf1-/-Il1rl1-/- mice with LCMV to induce 
FHL and compared them to both Control and α-ST2 FHL2 mice. Similar to α-ST2-
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treated Prf1-/- mice, Prf1-/-Il1rl1-/- mice were protected from mortality and weight loss 
(Figures 3.4C-D). Notably, Prf1-/-Il1rl1-/- mice maintained their body weight significantly 
better after LMCV infection than did α-ST2 treated Prf1-/- mice, suggesting that complete 
genetic ablation of ST2 has an even stronger protective effect than that mediated by 
antibody blockade (Figure 3.4D). Corresponding to these clinical improvements in 
disease, serum IFNγ levels were also sharply reduced in Prf1-/-Il1rl1-/- mice compared to 
Prf1-/- Control mice (Figure 3.4E). Prf1-/-Il1rl1-/- mice showed further similarity to α-ST2-
treated Prf1-/- mice in decreased numbers of both effector-phenotype and LCMV-specific 
CD8+ and CD4+ T cells relative to Prf1-/- Control mice (Figure 3.4F and data not shown). 
Finally, the IFNγ production defects noted in T cells from ST2-blocked Prf1-/- mice were 
also evident in Prf1-/-Il1rl1-/- mice, where the frequencies of IFNγ+ gp33-specific CD8+ T 
cells and the IFNγ MFI of these cells were significantly lower than in Prf1-/- Control mice 
(Figures 3.4G-H). Similarly reduced frequencies and per-cell IFNγ production were 
observed among IFNγ+ gp61-specific CD4+ T cells in Prf1-/-Il1rl1-/- mice, as well (data not 
shown). Thus, Prf1-/-Il1rl1-/- mice fully recapitulate the phenotype of α-ST2 antibody 
blockade in Prf1-/- mice, making them an ideal tool for dissecting the mechanisms of ST2 
enhancement of T cell-mediated inflammation.  
 
T cells require ST2 signaling after day 5 post-LCMV infection. 
IL-33/ST2 signaling is required for excessive accumulation and IFNγ production 
by LCMV-specific T cells, but the precise timepoint at which this cytokine becomes 
necessary to T cell function in FHL2 mice was unclear. Using a kinetic analysis of 
LCMV-infected Prf1-/- and Prf1-/-Il1rl1-/- mice, we found that LCMV-specific CD8+ and 
CD4+ T cells were identical in number between ST2-sufficient and -deficient mice up to 5 
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days post-infection (Figures 3.5A-B). Thereafter, they appeared to diverge, with a trend 
towards decreased numbers of LCMV-specific CD8+ and CD4+ T cells in Prf1-/-Il1rl1-/- 
mice by day 7 p.i., although this did not reach statistical significance (p=0.14 and p=0.12, 
respectively; Figures 3.5A-B). Coincident with these changes in number, disparities in 
LCMV-specific T cell function became apparent between days 5 and 7 p.i. The 
frequencies of gp33-specific CD8+ T cells and gp61-specific CD4+ T cells capable of 
producing IFNγ in response to cognate antigen stimulation were significantly decreased 
in Prf1-/-Il1rl1-/- mice compared to Prf1-/- mice by day 7 p.i. (Figures 3.5C-D). Defects in 
the median per-cell production of IFNγ among IFNγ+ LCMV-specific T cells in Prf1-/-Il1rl1-
/- mice relative to their ST2-sufficient counterparts mirrored these kinetics, as well 
(Figures 3.5E-F). These data demonstrate that ST2 signaling begins to impact the 
LCMV-specific T cell response sometime between days 5 and 7 p.i., which coincides 
with the timing of ST2 upregulation on CD8+ and CD4+ T cells in LCMV-infected WT 
mice (Bonilla et al., 2012). 
Since this time period is also marked by extensive proliferation of effector CD8+ 
and CD4+ T cells in response to LCMV (Murali-Krishna et al., 1998), we next 
investigated whether the decreased numbers of LCMV-specific T cells in Prf1-/-Il1rl1-/- 
mice were due to a defect in proliferative potential. Indeed, although the loss of ST2 
signaling did not prevent the majority of antigen-experienced T cells from expressing the 
proliferation marker Ki-67, the frequency of Ki-67+ CD44+CD8+ and CD44+CD4+ T cells 
was significantly decreased in Prf1-/-Il1rl1-/- mice compared to Prf1-/- mice (Figures 3.5G-
H). These data demonstrate qualitative differences at a population level among Prf1-/-
Il1rl1-/- T cells that may underlie the quantitative differences seen in these mice. 
Additionally, the frequency of CD44+ T cells induced to undergo apoptosis was actually 
decreased in Prf1-/-Il1rl1-/- mice relative to Prf1-/- mice, making it unlikely that enhanced T 
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cell death was responsible for the defects in accumulation of LCMV-specific T cells 
(Figures 3.5I-J). 
 
LCMV-specific T cells intrinsically require ST2 for enhanced expansion and IFNγ  
production in FHL2 mice 
 We next sought to determine whether the ST2 requirement of LCMV-specific 
effector Prf1-/- CD8+ and CD4+ T cells for enhanced expansion and function was cell-
intrinsic or extrinsic. We generated BM chimeras reconstituted with cells derived from a 
single donor genotype (Prf1-/- or Prf1-/-Il1rl1-/-) or a 1:1 mixture of the two (Mix). After 
eight weeks for reconstitution, these chimeras either remained uninfected (Uninf) or 
were infected with LCMV (Inf) and were analyzed 8 days p.i. Among effector CD8+ T 
cells, there was no difference in total numbers of Prf1-/- and Prf1-/-Il1rl1-/- cells between 
single donor-derived BM chimeras or within mixed BM chimeras when uninfected. 
However, LCMV infection induced a striking increase in Prf1-/- effector CD8+ T cells 
relative to Prf1-/-Il1rl1-/- cells within mixed BM chimeras, indicating that the reduced 
expansion of ST2-deficient Prf1-/- effector CD8+ T cells occurs in a cell-intrinsic manner 
(Figure 3.6A). Within the gp33-specific subset of this CD8+ T cell population, the 
proportion of cells derived from Prf1-/- hosts exceeded that from Prf1-/-Il1rl1-/- hosts in 
LCMV-infected mixed BM chimeras, demonstrating a similar cell-intrinsic requirement 
among LCMV-specific CD8+ T cells, as well (Figure 3.6B). Importantly, the ratio of Prf1-/- 
to Prf1-/-Il1rl1-/- CD8+ T cells was similar in uninfected mixed BM chimeras (Figure 3.6B). 
Effector CD4+ T cells also demonstrated a cell-intrinsic expansion requirement for ST2 
that was dependent on LCMV infection, with significantly fewer Prf1-/-Il1rl1-/- than Prf1-/- 
cells in infected mixed BM chimeras only (Figure 3.6C). While there was a slight skewing 
towards more Prf1-/-Il1rl1-/- CD4+ T cells in uninfected mixed BM chimeras, this difference 
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was reversed upon LCMV infection: similar to LCMV-specific CD8+ T cells, Prf1-/- gp61-
specific CD4+ T cells far outnumbered their Prf1-/-Il1rl1-/- counterparts within the same 
infected environment, indicating an intrinsic defect in Prf1-/-Il1rl1-/- cells (Figure 3.6D). 
 To delineate whether cell-intrinsic differences in proliferative capacity could 
account for the impaired expansion of Prf1-/-Il1rl1-/- T cells, we analyzed expression of Ki-
67 on antigen-experienced cells. Among both CD44+CD8+ (Figure 3.6E) and 
CD44+CD4+ (Figure 3.6F) T cells, we found reduced frequencies of Ki-67+ Prf1-/-Il1rl1-/- 
cells compared to Prf1-/- cells within the same infected host, even though there was no 
difference between the two genotypes in the absence of infection. Thus, Prf1-/- CD8+ and 
CD4+ T cells lacking ST2 demonstrate a cell-intrinsic defect in proliferation that leads to 
decreased expansion of these cells overall. 
 In addition to reduced proliferative capacity, we investigated whether ST2-
deficient T cells were intrinsically impaired in cytokine production, as well. As expected, 
there was a decreased frequency of Prf1-/-Il1rl1-/- IFNγ+ LCMV-specific CD8+ and CD4+ T 
cells compared to equivalent Prf1-/- cells between single-donor chimeras. Importantly, 
this disparity was recapitulated within mixed chimeras, indicating a cell-intrinsic reliance 
on ST2 (Figure 3.6G). Furthermore, median per-cell IFNγ production in response to 
LCMV gp33 or gp61 peptides was reduced in a cell-intrinsic manner in Prf1-/-Il1rl1-/- CD8+ 
and CD4+ T cells relative to their Prf1-/- counterparts (Figure 3.6H). The intrinsic ST2 
requirement of LCMV-specific Prf1-/- CD8+ T cells for maximal IFNγ production was also 
corroborated by similar findings in an adoptive transfer model (data not shown). 
Together, these data show that LCMV-specific T cells in FHL2 mice intrinsically require 
ST2 for enhanced expansion and IFNγ production, suggesting that these cells are 
directly hyperactivated by IL-33. 
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Discussion 
In this study, we have shown that ST2 signaling intrinsically promotes the 
expansion and IFNγ production of LCMV-specific Prf1-/- CD8+ and CD4+ T cells, which 
leads to systemic accumulation of supraphysiological IFNγ levels and subsequent lethal 
inflammation in FHL2 mice. ST2 enhances the proliferation and per-cell IFNγ production 
of effector T cells to augment both the number of cells producing IFNγ in response to 
viral antigens and the magnitude of this cytokine response. Notably, ST2 is not strictly 
required for the induction of functional antiviral effector T cells in Prf1-/- mice, suggesting 
that IL-33 is indeed an amplifier of the response, rather than a necessary differentiation 
factor. 
These data suggest a revised model for FHL2, in which IL-33, likely released 
from damaged tissue, couples with excessive antigen to directly drive effector T cell 
proliferation and IFNγ production, and thereby FHL immunopathology (Figure 3.7). This 
model of a two-signal requirement (both persistent antigen and specific danger signals) 
addresses several key aspects of FHL not previously accounted for: 1) why antigen 
alone is insufficient to induce FHL in genetically susceptible individuals; and 2) a reason 
for the requirement of MyD88 in the development of FHL. Furthermore, this model 
suggests that tissue damage dynamically influences the immunopathologic process and 
is not merely a passive result.  
Our findings reveal a cell-intrinsic ST2 signaling requirement of CD8+ and CD4+ T 
cells for effector expansion and IFNγ overproduction in FHL2 mice. This is consistent 
with previously published reports in LCMV-infected perforin-sufficient mice, showing that 
the accumulation and function of WT CD8+ and CD4+ T cells is regulated by ST2 in a 
cell-intrinsic manner (Baumann et al., 2015; Bonilla et al., 2012). Furthermore, CD8+ T 
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cells intrinsically require the ST2 signaling adaptor MyD88 for optimal accumulation of 
LCMV-specific effector cells after infection, although this is independent of IL-1R and IL-
18R (Bartholdy et al., 2009; Rahman et al., 2008; Rahman et al., 2011). However, the 
data presented here demonstrate differential effects of ST2 blockade in WT and Prf1-/- 
mice, particularly with respect to CD8+ T cell susceptibility to apoptosis. Bonilla et al. 
demonstrated reduced expression of the anti-apoptotic factor Bcl-2 in Il1rl1-/- transgenic 
gp33-specific CD8+ T cells compared to Il1rl1+/+ cells, suggesting that decreased survival 
might account for the failure of LCMV-specific cells to accumulate in the absence of ST2 
signaling (Bonilla et al., 2012). In contrast, we found decreased activation of caspases 3 
and 7 in CD44+ Prf1-/-Il1rl1-/- CD8+ T cells relative to Prf1-/- cells, indicating that enhanced 
apoptosis was unlikely to account for the overall decrease in numbers of Prf1-/-Il1rl1-/- 
effector CD8+ T cells. These divergent results may be attributable to differences in 
murine models used, CD8+ T cell subsets analyzed, or timepoints assessed; but it is also 
possible that Prf1-/- CD8+ T cells react differently to the loss of ST2 signaling than do 
perforin-sufficient cells. 
The earliest impact of ST2 signaling on the T cell response occurred between 
days 5 and 7 post-infection (Figure 3.6). It is not surprising that this window corresponds 
to the upregulation of ST2 on CD8+ and CD4+ T cells in the context of acute LCMV 
infection (Baumann et al., 2015; Bonilla et al., 2012); however, it is notable that this 
timeframe also coincides with the proliferative burst of LCMV-specific T cells (Murali-
Krishna et al., 1998). Effector CD8+ T cells are capable of dividing rapidly at this time, 
and considering the intrinsically increased frequency of proliferating cells among ST2-
sufficient CD8+ and CD4+ T cells, it is likely that small differences in effector cell numbers 
are quickly amplified in our model. Whether the T cell-intrinsic requirement of ST2 for 
elevated per-cell production of IFNγ is a proximal effect of ST2 signaling or a distal 
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manifestation of ST2-dependent alterations in effector T cell differentiation remains 
unclear. IL-33 signaling through ST2 activates several downstream pathways, including 
NF-κB, which is necessary for Th1 effector differentiation and cytotoxic CD8+ T cell 
function (Corn et al., 2003; Mora et al., 1999), as well as p38 MAPK, which both CD8+ 
and CD4+ T cells require for optimal IFNγ production (Merritt et al., 2000). Whether IL-33 
also promotes IFNγ production independent of TCR signaling in this model is also 
unclear. Bystander activation of CD8+ T cells is unlikely to contribute substantially to the 
inflammation in FHL (Lykens et al., 2011), and the majority of activated CD8+ T cells at 
the peak of the acute LCMV response are virus-specific (Murali-Krishna et al., 1998), 
making an antigen-independent mechanism of IFNγ overproduction less likely. However, 
given the general hypercytokinemia in FHL2 and the high degree of immune 
dysregulation, it is not inconceivable that IL-33, in combination with a STAT activator 
such as IL-12, may further enhance IFNγ production in this model. Investigation of the 
intracellular pathways responsible for the stimulatory effects of IL-33 in murine FHL may 
offer insight into these questions. 
A wide range of immune cell subsets expresses ST2 (Mirchandani et al., 2012), 
raising the possibility that other IL-33-responsive cells may play a role in FHL2 
pathophysiology. Of note, T regulatory (Treg) cells constitutively express high levels of 
ST2 and are induced by IL-33 to expand in a number of tissues (Matta et al., 2016; 
Schiering et al., 2014; Vasanthakumar et al., 2015); however, the relative balance of 
conventional and regulatory T cells has not been investigated in murine FHL. It may also 
prove valuable to explore the role of soluble ST2 (sST2), the natural negative regulator 
of IL-33, in murine FHL, since α-ST2 treatment likely blocks sST2, as well as membrane-
bound ST2. However, genetic ST2 deficiency, and thus complete absence of this decoy 
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receptor, phenocopied the biological effect of ST2 antibody blockade, making it unlikely 
that neutralization of sST2, leading to elevated free IL-33, would account for our findings.  
 In summary, we have shown that ST2 amplifies immunopathology in murine FHL 
by intrinsically enhancing proliferation and IFNγ production of LCMV-specific effector 
CD8+ and CD4+ T cells. These results suggest that acute administration of ST2-blocking 
antibodies may provide therapeutic benefit in FHL patients through diminution of not only 
systemic IFNγ but also tissue-infiltrating activated T cells. Whether such treatment may 
be beneficial long-term, however, will be the subject of the next chapter. 
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Figures 
 
 
Figure 3.1. Punctate IL-33 staining is consistent with lymphocyte responsiveness 
to IL-33 via ST2. 
(A) IL-33 immunohistochemistry in livers of LCMV-infected Prf1-/- mice 8 days p.i., with 
or without in vivo administration of ST2-blocking antibody on days 3, 5, and 7 p.i. 
Representative of 4 mice/group, original magnifications indicated. Arrows indicate 
examples of punctate perinuclear IL-33 staining; arrowheads indicate nuclear staining of 
IL-33+ cells. (B) IL-33 immunohistochemistry in livers of LCMV-infected WT, Prf1-/-, and 
Il33-/- mice 8 days p.i. Representative of 4 (WT, Prf1-/-) or 2 (Il33-/-) mice/group. Original 
magnification ×500. In (A-B), immunohistochemical staining was performed by Joanne 
Mauger and analyzed by Michele Paessler. 
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Figure 3.2. ST2 blockade decreases numbers of LCMV-specific effector CD8+ and 
CD4+ T cells in FHL2 mice. 
WT and Prf1-/- mice were infected with LCMV, treated with either α-ST2 (open circles, ) 
or Control (closed circles, ) antibodies on days 3, 5, and 7 p.i., and assessed on day 8 
p.i. Analyzed by linear mixed-effects model to account for baseline variability between 
experimental replicates: treatment and genotype were modeled as fixed effects, and 
experiment was treated as a random effect (e.g. intercept only). Significance of terms is 
denoted as follows: #, Genotype (WT vs. Prf1-/-); §, Treatment (Control vs. α-ST2); *, 
Interaction between Genotype and Treatment. (A,C) Representative flow plots gated on 
live CD90.2+CD8+ T cells (A) or CD90.2+CD4+ T cells (C), showing effector/memory 
phenotyping by CD44 and CD62L expression. (B,D) Numbers of splenic 
CD44hiCD62LloCD127lo effector CD8+ T cells (B) or CD4+ T cells (D). N=17-18 
mice/group, data pooled from 4 independent experiments. (E) Representative flow plots 
gated on live CD90.2+CD8+ T cells, showing gp33 MHC Class I tetramer staining. (F) 
Numbers of splenic gp33-specific CD8+ T cells (n=13-14 mice/group, data pooled from 3 
independent experiments). (G) Representative flow plots gated on live CD90.2+CD4+ T 
cells, showing gp66 MHC Class II tetramer staining. (H) Numbers of splenic gp66-
specific CD4+ T cells (n=9-10 mice/group, data pooled from 2 independent experiments).  
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Figure 3.3. The frequency and IFNγ  production capacity of IFNγ+ LCMV-specific T 
cells are reduced in FHL2 mice receiving ST2 blockade. 
WT and Prf1-/- mice were infected with LCMV, treated with either α-ST2 (open circles, ) 
or Control (closed circles, ) antibodies on days 3, 5, and 7 p.i., and assessed on day 8 
p.i. N=12-13 mice/group, data pooled from 3 independent experiments. Analyzed by 
linear mixed-effects model to account for baseline variability between experimental 
replicates: treatment and genotype were modeled as fixed effects, and experiment was 
treated as a random effect. Significance of terms is denoted as follows: #, Genotype (WT 
vs. Prf1-/-); §, Treatment (Control vs. α-ST2); *, Interaction between Genotype and 
Treatment. (A,C) Representative flow plots gated on live CD90.2+CD8+ T cells (A) or 
CD90.2+CD4+ T cells (C), showing intracellular IFNγ expression in response to in vitro 
gp33 (A) or gp61 (C) peptide stimulation. (B,D) Summary data showing frequencies of 
IFNγ+ LCMV-specific CD8+ T cells (B) and CD4+ T cells (D). (E-F) Summary data 
showing median IFNγ fluorescence intensity of CD8+ T cells (E) and CD4+ T cells (F) 
producing IFNγ in response to restimulation with LCMV peptides. MFI is normalized to 
WT Control mean for each experiment.  
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Figure 3.4. Prf1-/-Il1rl1-/- mice resemble ST2-blocked Prf1-/- mice in pathologic and 
non-pathologic states. 
(A-B) Baseline characteristics of splenocytes from uninfected Prf1-/- and Prf1-/-Il1rl1-/- 
mice. N=3 mice/group. (A) Total numbers of immune cell subsets. No significant effect of 
genotype in two-way ANOVA. (B) Representative flow plots of T cells. Numbers indicate 
frequency of gated population out of parent population. Top row, gated on live 
TCRβ+CD90.2+CD19- cells. Middle row, gated on live TCRβ+CD90.2+CD8+ cells. Bottom 
row, gated on live TCRβ+CD90.2+CD4+ cells. (C) Survival of LCMV-infected Prf1-/- mice 
receiving isotype control antibody (Prf1-/- Control, n=10), Prf1-/- mice receiving ST2-
blocking antibody (Prf1-/- α-ST2, n=9) and untreated Prf1-/-Il1rl1-/- mice (n=14). Antibody 
treatments were administered on day 3 p.i. and every other day thereafter. Analyzed by 
log-rank (Mantel-Cox) test. (D) Body weight of Prf1-/- Control, Prf1-/- α-ST2, and Prf1-/-
Il1rl1-/- mice. Symbols represent mean ± SEM of 9-14 mice. Prf1-/- α-ST2 and Prf1-/-Il1rl1-
/- mice were analyzed by two-way repeated measures ANOVA. (E-H) Analysis of Prf1-/- 
Control, Prf1-/- α-ST2, and Prf1-/-Il1rl1-/- mice 8 days post-LCMV infection. N=4 
mice/group. Analyzed by one-way ANOVA; significance of Tukey’s post-test comparing 
all groups is indicated. (E) Serum IFNγ level. (F) Numbers of splenic gp33-specific CD8+ 
T cells. (G) Frequencies and (H) median IFNγ fluorescence intensity of IFNγ+ gp33-
specific CD8+ T cells. 
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Figure 3.5. T cells require ST2 signaling after day 5 post-LCMV infection. 
(A-F) T cells from LCMV-infected Prf1-/- and Prf1-/-Il1rl1-/- mice were analyzed at days 3, 
5, and 7 p.i. Symbols represent mean ± SEM of n=3-8 mice/timepoint/genotype. Data 
are pooled from 2 independent experiments. Day 7 timepoint analyzed by Student’s two-
tailed t-test. (A-B) Total splenic numbers of gp33-tetramer+ CD8+ T cells and gp61-
tetramer+ CD4+ T cells. (C-D) Frequencies of IFNγ+ LCMV-specific CD8+ T cells and 
CD4+ T cells. (E-F) Median IFNγ fluorescence intensity of CD8+ T cells and CD4+ T cells 
producing IFNγ in response to restimulation with LCMV peptides gp33 and gp61, 
respectively. (G-J) CD44+ T cells from LCMV-infected Prf1-/- and Prf1-/-Il1rl1-/- mice were 
analyzed at day 7 p.i. N=4 mice/genotype. Analyzed by Student’s two-tailed t-test. (G-H) 
Frequencies of Ki-67+ CD8+ T cells and CD4+ T cells. (I-J) Frequencies of CD8+ T cells 
and CD4+ T cells staining positively with fluorescent inhibitor of caspases 3 and 7 
(FLICA).  
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Figure 3.6. LCMV-specific T cells intrinsically require ST2 for enhanced expansion 
and IFNγ  production in FHL2 mice. 
BM chimeras reconstituted with cells from Prf1-/- donors (P-/-), Prf1-/-Il1rl1-/- donors (P-/-I-/-), 
or a 1:1 mixture (Mix) were either left uninfected (Uninf) or were infected with LCMV (Inf) 
and analyzed 8 days p.i. N=4-5 mice/group. Single-donor chimeras were analyzed by 
unpaired two-way Student’s t-test (P-/- vs. P-/-I-/-); Prf1-/- and Prf1-/-Il1rl1-/- cells within 
mixed chimeras were analyzed by paired two-way Student’s t-test. (A) Numbers of 
CD44+CD62L- effector CD8+ T cells. (B) Frequencies of Prf1-/- or Prf1-/-Il1rl1-/- cells 
among total CD8+ T cells in uninfected mixed chimeras (left), or among gp33 tetramer+ 
CD8+ T cells in infected mixed chimeras (right). (C) Numbers of CD44+CD62L- effector 
CD4+ T cells. (D) Frequencies of Prf1-/- or Prf1-/-Il1rl1-/- cells among total CD4+ T cells in 
uninfected mixed chimeras (left), or among gp61 tetramer+ CD4+ T cells in infected 
mixed chimeras (right). (E-F) Frequencies of Ki-67+ cells among CD44+ CD8+ or CD4+ T 
cells derived from Prf1-/- or Prf1-/-Il1rl1-/- donors. (G) Frequencies of IFNγ+ LCMV-specific 
CD8+ and CD4+ T cells. (H) Median IFNγ fluorescence intensity of CD8+ and CD4+ T 
cells producing IFNγ in response to restimulation with LCMV peptides gp33 and gp61, 
respectively. 
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Figure 3.7. Proposed model of FHL pathophysiology. 
In the traditional paradigm (left circle, connected by blue arrows), APCs and LCMV-
infected cells present viral antigens to LCMV-specific T cells, activating them to secrete 
IFNγ. IFNγ acts back on APCs to enhance their ability to present antigen, setting up a 
positive feedback loop. In Prf1-/- mice, T cells are unable to eliminate APCs via perforin, 
resulting in a loss of negative regulation that enables uninhibited amplification of 
inflammation. In our revised model, IL-33 signaling (right circle, connected by orange 
arrows) further amplifies this vicious cycle. Tissue damage and cell death leads to the 
release of IL-33, which acts directly on LCMV-specific T cells to further promote their 
expansion and production of IFNγ. Elevated IFNγ exacerbates immunopathology, 
leading to further release of IL-33 from dying cells. 
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Chapter 4: 
Prolonged ST2 blockade enables CD8+ T cell exhaustion that protects 
against chronic wasting in FHL2 mice 
 
Introduction 
We have demonstrated that disruption of ST2 signaling restricts the accumulation 
and IFNγ production of effector LCMV-specific CD8+ and CD4+ T cells, leading to lower 
systemic levels of pathologic IFNγ in the murine model of FHL2. This modulation of the 
major pathogenic factors in the disease markedly improves morbidity and mortality in 
FHL2 mice, raising the possibility that ST2 blockade may confer similar protection in 
patients with FHL if applied therapeutically. However, the long-term impact of ST2 
blockade on the dynamics of the disease and the T cell compartment are incompletely 
understood, since our studies thus far have focused primarily on the acute effects of 
treatment. 
 We have previously demonstrated that ST2 blockade enables mice to survive at 
least 30 days post-infection, and there is a modest therapeutic benefit in continuing ST2 
blockade at later timepoints, since withdrawal at day 18 leads to significantly greater 
weight loss (Figure 2.3C). It is unclear whether this late protective effect of ST2 blockade 
is T cell-mediated. It is possible that withdrawal of ST2 blockade and restoration of IL-33 
responsiveness could lift the constraint on T cells and enable them to become 
hyperactivated again. Alternatively, T cells may have become stably subdued by early 
ST2 blockade and the later effects of continued treatment are mediated through different 
pathways. This is a particularly relevant possibility in light of the related murine model of 
FHL4, in which disease develops transiently in syntaxin-11-deficient (Stx11-/-) mice 
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following LCMV infection but gradually becomes quiescent as the CD8+ T cell pool 
undergoes a functional decline known as exhaustion (Kögl et al., 2013). 
CD8+ T cell exhaustion is a progressive, step-wise loss of effector functions that 
occurs in the context of persistently high levels of antigen. Early signs include diminished 
IL-2 production, followed by sequential loss of TNFα, IFNγ, and cytotoxicity (Wherry et 
al., 2003). This functional impairment coincides with the gradual upregulation of 
inhibitory molecules, such as PD-1, 2B4, and Lag-3 (Barber et al., 2005; Blackburn et 
al., 2008). Over time, exhausted CD8+ T cells lose their ability to proliferate and become 
increasingly susceptible to apoptosis, eventually being deleted from the host altogether 
(Kahan et al., 2015). This process is highly dependent on levels of antigen perceived by 
CD8+ T cells, as restriction of MHC I-dependent antigen availability delays exhaustion 
(Mueller and Ahmed, 2009). Furthermore, lack of CD4+ T cell help worsens the severity 
of exhaustion by indirectly impairing the quality of CD8+ T cell priming, as well as by 
inadequate cytokine support (Kahan et al., 2015). Ultimately, CD8+ T cell exhaustion 
prevents the complete resolution of infection and simultaneously impairs establishment 
of a functional memory CD8+ T cell response (Wherry et al., 2004). Exhaustion is 
therefore considered a major obstacle in the treatment of chronic infections, such as HIV 
and HCV, and malignancy.  
However, exhaustion likely evolved as a protective negative feedback 
mechanism to prevent the development of immunopathology or other inappropriate 
immune responses such as autoimmunity. Manipulation of CD8+ T cell exhaustion in 
experimental murine models frequently tips the balance from insufficient antiviral 
immunity to immunopathology, as exemplified by the spontaneous development of 
autoimmunity in PD-1-deficient mice and by the fatal CD8+ T cell-mediated disease 
suffered by PD-1- and PD-L1-deficient mice upon LCMV infection (Barber et al., 2005; 
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Frebel et al., 2012; Nishimura et al., 2001). Clinical efforts to reverse exhaustion, by 
administration of checkpoint inhibitors such as CTLA-4- or PD-1-blocking antibodies, can 
lead to adverse effects such as the development of autoimmune disease (Kong and 
Flynn, 2014). Furthermore, patients with autoimmune diseases such as antibody-
associated vasculitis or SLE whose CD8+ T cells show an exhausted transcriptional 
signature have a better clinical prognosis than patients without this signature (McKinney 
et al., 2015). By ultimately failing to respond to the underlying source of immune 
stimulation, CD8+ T cell exhaustion can be an effective short-term strategy for prolonging 
immune-mediated disease-free survival. In the case of FHL4 mice, CD8+ T cell 
exhaustion likely enables the mice to survive; conversely, the CD8+ T cells in FHL2 mice 
fail to undergo exhaustion, leading to overwhelming inflammation and mortality. 
With the use of ST2 blockade to prolong survival in FHL2 mice, we can now 
assess how the CD8+ T cell response in Prf1-/- mice changes over time, and how ST2 
modulates that response. We find that in the setting of ST2 blockade, LCMV-specific 
CD8+ T cells in FHL2 mice gradually become exhausted. This outcome relies on ST2 
blockade during only the first two weeks of infection, suggesting that ST2 blockade 
indirectly promotes exhaustion by prolonging survival. Finally, reversal of exhaustion in 
ST2-deficient Prf1-/- mice via PD-L1 blockade worsens chronic weight loss, suggesting 
that CD8+ T cell exhaustion is protective late in the course of disease. Thus, ST2 
blockade enables long-term survival and CD8+ T cell exhaustion in FHL2 mice and if 
used therapeutically, is likely to provide the greatest benefit as prophylaxis or during 
acute flares. 
 
 
  
59 
 
Results 
Prf1-/- CD8+ T cells are highly responsive to persistent viremia 15 days post-
infection in the setting of ST2-blockade 
In order to investigate the long-term effects of ST2 blockade on the CD8+ T cell 
response, we first assessed T cell numbers and function at 15 days post-infection (p.i.), 
one week later than previous assessments. We expected that ST2 blockade would 
continue to impair the T cell response, but instead found progressive expansion of gp33-
specific CD8+ T cells in α-ST2-treated Prf1-/- mice at day 15 p.i. (Figure 4.1A), with an 
even greater number present than at day 8 (Figure 3.2F). In contrast, LCMV-infected WT 
mice demonstrated equivalently low numbers of gp33-specific CD8+ T cells with or 
without ST2 blockade, as would be expected in the setting of viral clearance and 
contraction of the effector response (Figure 4.1A). Furthermore, ST2-blocked Prf1-/- 
CD8+ T cells remained highly functional at day 15 p.i., as an average of 44.7% produced 
IFNγ in response to a pool of LCMV peptides representing major CD8+ T cell epitopes 
(Figures 4.1B-C). While ST2 blockade significantly lowered the frequency of IFNγ+ 
LCMV-specific CD8+ T cells in WT mice, it was insufficient to reduce the frequency of 
these cells in Prf1-/- mice to the level of Control WT mice, as had been seen at day 8 p.i. 
(Figure 3.3B). Thus, even in the setting of ST2 blockade, Prf1-/- CD8+ T cells were not 
quiescent 15 days p.i. but rather were highly responsive and even more abundant, 
suggesting they continued to receive cognate antigen stimulation. Consistent with this 
hypothesis, we found that splenic LCMV titers remained high in α-ST2-treated Prf1-/- at 
15 days p.i., and in fact were sustained at these levels as late as 30 days p.i. (Figure 
4.1D). These data are consistent with previously published reports of the inability of Prf1-
/- mice to eliminate LCMV (Lykens et al., 2011); however, they present a paradox as to 
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how ST2-blocked Prf1-/- mice survive sustained high levels of viral replication, given the 
highly active nature of the CD8+ T cell response at day 15 p.i.  
 
Expansion of gp33-specific CD8+ T cells peaks in ST2-blocked Prf1-/- mice at day 
15 p.i. before a precipitous decline  
Because the lethality of the FHL2 model precludes comparison of Prf1-/- CD8+ T 
cell responses in the presence or absence of ST2 blockade later than day 8 p.i., we 
investigated the evolution of the CD8+ T cell response in the setting of ST2 blockade by 
conducting a longitudinal analysis. We examined CD8+ T cells from α-ST2-treated Prf1-/- 
mice at days 8, 15, and 30 p.i. First looking broadly at bulk CD44hiCD62Llo effector CD8+ 
T cells, we found that while the number of these cells increased from day 8 to day 15, it 
declined substantially by day 30 post-infection (Figure 4.2A). In contrast, naïve and 
memory CD8+ T cell populations did not change appreciably in number over the course 
of infection, with the exception of a decrease in memory CD8+ T cells from day 15 to day 
30 (Figure 4.2A). The gp33-specific subset of these cells showed similar kinetics, 
peaking at day 15 and decreasing by day 30 (Figure 4.2B). This late-stage decrease in 
cell numbers coincided with a reduction in the frequency of Ki-67-expressing cells 
among gp33-specific CD8+ T cells, indicating reduced proliferation (Figure 4.2C). 
Together, these data suggest that while LCMV-specific Prf1-/- CD8+ T cells continue to 
expand for a period of time in the setting of ST2 blockade, they gradually lose 
proliferative potential and become unable to maintain their numbers by 30 days p.i.  
 
Prf1-/- gp33-specific CD8+ T cells gradually develop exhaustion in the setting of 
ST2 blockade 
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Despite the initial expansion of LCMV-specific CD8+ T cells until day 15 p.i., their 
eventual decline raised the possibility of exhaustion occurring within the Prf1-/- effector 
CD8+ T cell pool. Such a mechanism might also account for the ability of ST2-blocked 
Prf1-/- mice to survive long-term in the setting of persistently high viral replication. To 
determine whether Prf1-/- CD8+ T cells were undergoing exhaustion in the setting of ST2 
blockade, we first examined their phenotype for inhibitory marker expression. In contrast 
to gp33-specific CD8+ T cells from LCMV-immune WT mice, those in ST2-blocked Prf1-/- 
mice demonstrated consistently elevated expression of the inhibitory markers PD-1 and 
2B4, with a gradual increase in MFI from day 8 to day 30 p.i., suggesting progressive 
functional impairment (Figures 4.3A-B). In parallel experiments, gp33-specific CD8+ T 
cells from Prf1-/-Il1rl1-/- mice also displayed higher expression of PD-1 and 2B4 30 days 
post-LCMV infection, compared to LCMV-immune WT mice (data not shown). 
Because PD-1 expression also correlates with viral load and is insufficient to 
determine exhaustion (Hong et al., 2013; Migueles et al., 2009), we assessed 
expression of the key transcription factors T-bet and Eomesodermin (Eomes). 
Differential expression of these transcription factors identifies two subsets of exhausted 
cells: a progenitor T-bethi Eomeslo PD-1int population and its terminally exhausted 
Eomeshi T-betlo PD-1hi progeny (Paley et al., 2012). The majority of gp33-specific CD8+ T 
cells at day 8 p.i. were among the T-bethi PD-1int pool (Figure 4.3C). However, by day 30 
p.i. they had mostly converted to Eomeshi PD-1hi (Figure 4.3C), a transition evident by 
the gradual decrease in the ratio of T-bet:Eomes MFI (Figure 4.3D). Thus, in the setting 
of ST2 blockade, Prf1-/- CD8+ T cells undergo phenotypic changes consistent with 
exhaustion.  
To determine whether these cells were truly exhausted, we measured the ability 
of ST2-blocked Prf1-/- CD8+ T cells to produce cytokine in response to gp33 peptide. 
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Although these cells lack perforin and thus are unable to mediate cytotoxicity, we 
assessed their ability to degranulate, as another proxy for functional capacity. At day 8 
p.i., gp33-specific CD8+ T cells showed almost no IL-2 and very little TNFα production 
(Figure 4.4), which may be due to either the particular nature of the IFNγ-dominated Prf1-
/- response or the early loss of these effector functions due to exhaustion. 
Simultaneously, these cells demonstrated robust IFNγ production and degranulation, as 
measured by externalization of CD107a (Figure 4.4). However, by day 15, TNFα 
production by gp33-specific Prf1-/- CD8+ T cells decreased to negligible levels (Figure 
4.4). The IFNγ production and degranulation capacity of these cells showed progressive 
decreases over time, both in terms of the frequency of responding cells, as well as the 
potency of that response, as measured by MFI (Figure 4.4). Of note, the median per-
CD8+ T cell expression of effector molecules at 30 days p.i. was consistently lower in α-
ST2-treated Prf1-/- mice than LCMV-immune WT mice (Figure 4.4), suggesting that ST2-
blocked Prf1-/- mice failed to develop a functional memory CD8+ T cell response. Rather, 
their CD8+ T cells demonstrated the hierarchical loss of function that typifies CD8+ T cell 
exhaustion. Prf1-/-Il1rl1-/- mice similarly exhibited decreased frequencies of IFNγ+ and 
TNFα+ gp33-specific CD8+ T cells, as well as reduced per-cell production of these 
cytokines, at 30 days p.i. compared to LCMV-immune WT mice (data not shown). 
Therefore, while the LCMV-specific CD8+ T cell response in Prf1-/- mice appeared 
hyperactivated at day 15 p.i., it ultimately became exhausted by day 30 p.i. in the setting 
of ST2 blockade. 
 
Withdrawal of ST2 blockade does not reverse CD8+ T cell exhaustion 
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While ST2 blockade evidently enables the development of CD8+ T cell 
exhaustion in Prf1-/- mice, it remained unclear how this outcome was mediated. One 
possibility was that disruption of ST2 signaling directly induced an exhaustion program in 
CD8+ T cells; alternatively, ST2 blockade may have promoted exhaustion indirectly, by 
prolonging survival of the mice such that their CD8+ T cells underwent the standard 
reaction to persistently high viremia. Because it was not feasible to differentiate between 
these two possibilities by extending the survival of Control Prf1-/- mice in the absence of 
ST2 blockade, we chose the alternative approach of withdrawing ST2 blockade from α-
ST2-treated mice. FHL2 mice were treated with the normal α-ST2 regimen until day 15 
p.i., at which time half of these mice were switched to isotype control antibody treatment, 
providing a Withdrawal group. At 30 days p.i., Prf1-/- mice withdrawn from ST2 blockade 
showed similarly low numbers of total effector and gp33-specific CD8+ T cells as mice 
continuously treated with α-ST2 (Figure 4.5A and data not shown). Consistent with these 
findings, the frequency of proliferating Ki-67+ gp33-specific CD8+ T cells was unchanged 
by α-ST2 withdrawal (Figure 4.5B). LCMV gp33-specific CD8+ T cells from ST2-blocked 
and Withdrawal mice were phenotypically indistinguishable, with both groups showing 
equally high PD-1 and 2B4 expression (Figure 4.5C and data not shown). Moreover, 
similar frequencies of gp33-specific CD8+ T cells segregated with the Eomeshi PD-1hi 
subset of terminally exhausted cells in Withdrawal mice as in mice receiving continual α-
ST2 treatment (Figure 4.5D). Most importantly, withdrawal of ST2 blockade did not affect 
the loss of effector functions seen 30 days p.i.: both groups of mice demonstrated 
equivalently low frequencies of IFNγ+ gp33-specific cells and low per-cell IFNγ production 
(Figure 4.5E). The frequency and expression level of TNFα and IL-2 were also 
unaltered, as was degranulation (data not shown). Together, these findings demonstrate 
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that withdrawal of ST2 blockade fails to reverse exhaustion. Therefore, disruption of IL-
33 signaling is only required early in the course of disease for the eventual development 
of CD8+ T cell exhaustion, suggesting that ST2 blockade either directly induces 
exhaustion shortly after infection or indirectly promotes it by maintaining the early 
survival of the host.  
 
CD8+ T cell exhaustion in chronically-infected perforin-sufficient mice is largely 
independent of ST2 
 To further investigate whether ST2 blockade directly or indirectly promotes 
exhaustion, we turned to a classic model of CD8+ T cell exhaustion: infection with the 
Clone 13 variant of LCMV. Although LCMV Clone 13 (Cl-13) differs from LCMV 
Armstrong (Arm) by only two amino acids, it exhibits broader tropism and produces a 
more severe infection (Oldstone, 2001). WT mice become persistently viremic when 
infected with Cl-13 and their CD8+ T cells begin to develop signs of exhaustion by day 
15 p.i., with severe signs developing by day 30 and beyond; in contrast, WT mice ably 
clear Arm by 8 days p.i. and thereafter exhibit robust memory CD8+ T cell responses. To 
determine whether ST2 impacts the development of CD8+ T cell exhaustion in general, 
we infected WT and Il1rl1-/- mice with Cl-13 and compared their CD8+ T cell responses 
15 days p.i. to the functional effector CD8+ T cell response of WT mice 8 days post-Arm 
infection. The total number of effector CD8+ T cells was similar in Il1rl1-/- Cl-13-infected 
mice compared to WT Cl-13-infected mice, although both were markedly decreased 
relative to acutely infected mice (Figure 4.6A), consistent with an exhausted CD8+ T cell 
response. Total numbers of gp33-specific CD8+ T cells were also similarly low among 
chronically infected mice, regardless of ST2 status (Figure 4.6B). Among these LCMV-
specific CD8+ T cells, both Il1rl1-/- and WT mice infected with Cl-13 showed equivalently 
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high frequencies expressing the inhibitory receptors PD-1 and 2B4, indicative of an 
exhausted phenotype (Figures 4.6C-D), and comparatively low frequencies expressing 
Ki-67, suggesting reduced proliferative capacity (Figure 4.6E). In sharp contrast to the 
effector gp33-specific CD8+ T cells in Arm-infected WT mice, the majority of gp33-
specific CD8+ T cells in Cl-13-infected mice resembled Eomeshi PD-1hi terminally 
exhausted cells, with a modest increase in Il1rl1-/- compared to WT mice (Figure 4.6F). 
The frequencies of gp33-specific CD8+ T cells capable of producing IL-2, TNFα, or IFNγ 
were similarly decreased in both Il1rl1-/- and WT Cl-13-infected mice relative to the 
robust effector response in Arm-infected WT mice, demonstrating that ST2 signaling 
does not affect the ability of CD8+ T cells to become exhausted (Figure 4.6G). 
Interestingly, Il1rl1-/- mice infected with Cl-13 showed lower frequencies of gp33-specific 
cells degranulating than even WT mice infected with Cl-13 (Figure 4.6G). Whether this 
decrease represents a more advanced state of exhaustion or a downstream defect of 
altered effector differentiation in the absence of ST2 is difficult to assess from this single 
timepoint. Overall, the LCMV-specific CD8+ T cell response to Cl-13 infection was 
comparably exhausted in Il1rl1-/- and WT mice, suggesting that disruption of ST2 
signaling does not directly impact the development of CD8+ T cell exhaustion. 
 
Reversal of exhaustion partially protects FHL2 mice from chronic weight loss 
Our data thus far suggest that the development of CD8+ T cell exhaustion is a 
consequence, rather than a cause, of prolonged survival in ST2-blocked FHL2 mice. 
However, by dampening the late-stage CD8+ T cell response against continual antigen 
stimulation, exhaustion is likely to further reduce inflammation and disease in FHL2 
mice, as has been demonstrated in FHL4 mice (Kögl et al., 2013). To determine whether 
CD8+ T cell exhaustion provides additional late-stage clinical benefit beyond the acute 
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protection provided by ST2 blockade, we pharmacologically reversed CD8+ T cell 
exhaustion in LCMV-infected Prf1-/-Il1rl1-/- mice. Beginning at day 15 p.i., when PD-1 is 
highly upregulated on ST2-blocked Prf1-/- LCMV-specific CD8+ T cells (Figure 4.3A), we 
administered α-PD-L1 antibody treatment, which blocks the interaction of PD-1 with one 
of its ligands and transiently enhances the effector function of exhausted CD8+ T cells 
(Barber et al., 2005; Blackburn et al., 2008). Mice receiving PD-L1 blockade lost 
significantly more weight over the two-week treatment period (Figure 4.7), suggesting 
that exhaustion protects against chronic wasting in FHL2 mice. However, the fact that α-
PD-L1 blockade did not enhance mortality suggests that the protection afforded by 
exhaustion is partial. Thus, while CD8+ T cell exhaustion is not the only factor reducing 
disease in persistently viremic FHL2 mice, it provides a significant clinical benefit.  
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Discussion 
Together, our findings suggest that early ST2 blockade prolongs survival in FHL2 
mice and allows for the development of CD8+ T cell exhaustion, which provides partial 
protection from morbidity late in the course of disease. 
 This study establishes that the development of exhaustion in FHL mice, and 
subsequent improvement in disease, is not restricted to Stx11-/- mice; rather, Prf1-/- CD8+ 
T cells are also capable of undergoing exhaustion, under the right circumstances. The 
similarity of outcomes in FHL4 mice and ST2-blocked FHL2 mice suggests that reduced 
severity of disease, and thus prolonged survival, accounts for the ability of these mice to 
develop an exhausted CD8+ T cell response. It is likely that any number of different 
conditions capable of blunting inflammation and extending survival – whether 
neutralization of IFNγ, LCMV, or some other factor – would have a similar effect. 
However, unlike Stx11-/- mice, reversal of exhaustion did not convert FHL in Prf1-/-Il1rl1-/- 
mice to a fatal disease (Kögl et al., 2013). It is possible that technical reasons underlie 
this difference, as a fatal outcome was achieved in Stx11-/- mice with the combined 
blockade of PD-L1 and Lag-3, a combination shown to enhance CD8+ function above 
that of PD-L1 blockade (Blackburn et al., 2008), and antibody treatment was begun 
several days earlier in that model compared to ours. Regardless, our data suggest that 
exhaustion likely accounts for only part of the protective effect seen in Prf1-/- mice with 
ST2 blockade. The fact that Control Prf1-/-Il1rl1-/- mice began to decline in weight around 
days 23-30 p.i. suggests that other pathogenic factors besides CD8+ T cells and IFNγ 
may act later in the course of disease. These could include late downstream 
consequences of the inflammation and organ damage experienced acutely.  
Given the minimal impact of ST2 deficiency on CD8+ T cell exhaustion in 
perforin-sufficient mice (Figure 4.6), the ability of ST2 blockade to promote exhaustion in 
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FHL2 mice is likely mediated through an indirect mechanism. Disruption of ST2 signaling 
reduces the severity of acute weight loss, liver damage, and cytopenias (Figures 2.3 and 
2.4), ultimately minimizing end-organ damage and extending the lifespan of the host. 
This essentially “buys time” for the CD8+ T cells, until the persistently high levels of 
antigen in FHL2 mice inevitably drive the process of exhaustion (Bucks et al., 2009; 
Mueller and Ahmed, 2009). The life-sustaining supportive care provided to human 
patients with FHL similarly extends survival, although whether CD8+ T cell exhaustion 
occurs in these patients is unknown, due to the rapid initiation of immunosuppressive 
therapy upon diagnosis. While less likely, a definitive role for ST2 blockade in actively 
promoting CD8+ T cell exhaustion cannot be ruled out. If ST2 blockade were to directly 
induce a transcriptional and/or epigenetic program in CD8+ T cells leading to their 
exhaustion, we would expect the kinetics of exhaustion to be accelerated in Il1rl1-/- mice. 
Based on our data at a single timepoint, it is difficult to determine whether the similar 
degree of exhaustion observed in Il1rl1-/- and WT CD8+ T cells at 15 days p.i. results 
from a comparable functional decline or different baselines. Future experiments to 
characterize the initial CD8+ T cell response in Il1rl1-/- mice at earlier time points may be 
informative in this matter. However, it remains most likely that blockade of the IL-33/ST2 
pathway does not mediate CD8+ T cell exhaustion directly.  
We therefore propose a conceptual model to explain the relationship between 
CD8+ T cell responsiveness and disease outcome in FHL mice (Figure 4.8). Rather than 
an inability of Prf1-/- CD8+ T cells to undergo exhaustion, it is the kinetics of disease, in 
the context of the entire organism, that is the key factor determining survival. LCMV 
infection in Prf1-/- mice is lethal not because of a failure of exhaustion, but because the 
magnitude of acute inflammation in these mice is so high that immunopathologic 
damage rapidly exceeds their capacity to compensate; they succumb to multi-organ 
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failure before their CD8+ T cells have an opportunity to become exhausted. However, 
disruption of ST2 signaling in these mice sufficiently suppresses inflammation to 
maintain them within confines compatible with life; as they survive, their CD8+ T cells 
naturally undergo exhaustion, which further protects the mice from immune-mediated 
disease. Similarly, syntaxin-11 deficiency, which is intrinsically less severe than perforin 
deficiency (Jessen et al., 2013; Kögl et al., 2013), allows mice with defective cytotoxicity 
to survive long-term, thereby enabling the development of CD8+ T cell exhaustion. Such 
a model provides an explanation as to why exhaustion has not been observed in FHL2 
mice previously. Furthermore, it suggests that the primary therapeutic benefit of ST2 
blockade derives not from an ability to induce exhaustion, but to limit early 
immunopathology. 
In summary, we have shown that the early immune-regulatory benefits of ST2 
blockade in murine FHL2 are extended through the eventual onset of CD8+ T cell 
exhaustion, which provides partial protection against chronic wasting later in the course 
of disease. Our work thus suggests that pharmacologic inhibition of the IL-33/ST2 axis 
may offer a promising new therapeutic strategy for the treatment of FHL. 
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Figures 
 
 
Figure 4.1. Prf1-/- CD8+ T cells are highly responsive to persistent viremia 15 days 
post-infection in the setting of ST2-blockade. 
WT and Prf1-/- mice were infected with LCMV, treated with either α-ST2 or Control 
antibodies on day 3 p.i. and every other day thereafter, and assessed on day 15 p.i. (A) 
Numbers of gp33-specific CD8+ T cells. N=4 mice/group. Analyzed by one-way ANOVA; 
significance of Tukey’s post-test comparing all groups is indicated. (B) Representative 
flow plots gated on live CD90.2+CD8+ T cells, showing intracellular IFNγ expression in 
response to in vitro gp33 peptide stimulation. (C) Summary data showing frequencies of 
IFNγ+ gp33-specific CD8+ T cells. Analyzed by one-way ANOVA; significance of Tukey’s 
post-test comparing all groups is indicated. (D) Splenic LCMV titer. Symbols represent 
mean ± SEM of 3-4 mice. Dotted line indicates limit of detection of plaque assay. 
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Figure 4.2. Expansion of gp33-specific CD8+ T cells peaks in ST2-blocked Prf1-/- 
mice at day 15 p.i. before a precipitous decline. 
Prf1-/- mice were infected with LCMV, treated every other day with α-ST2 antibody 
beginning on day 3 p.i., and assessed on days 8, 15, or 30 p.i. N=3-4 mice/group. 
Analyzed by one-way ANOVA; significance of Tukey’s post-test comparing all groups is 
indicated. (A) Total numbers of splenic CD8+ T cells, divided into naïve (CD44lo), effector 
(CD44hiCD62Llo), and memory (CD44hiCD62Lhi) subsets. Significance of changes among 
the effector subset only is shown; no significant differences were observed in naïve or 
memory subsets, except for a decrease in the number of memory-phenotype cells 
between days 15 and 30 p.i. (p < 0.01). (B) Numbers of gp33-specific CD8+ T cells. (C) 
Frequencies of gp33-tetramer+ CD8+ T cells expressing Ki-67. 
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Figure 4.3. Prf1-/- gp33-specific CD8+ T cells develop phenotypic hallmarks of 
exhaustion with prolonged ST2 blockade. 
Prf1-/- mice were infected with LCMV, treated every other day with α-ST2 antibody 
beginning on day 3 p.i., and assessed on days 8, 15, or 30 p.i. WT mice infected with 
LCMV and analyzed 30 days p.i. provided an LCMV-immune control. N=3-4 mice/group. 
(A) Representative histograms gated on gp33-tetramer+ CD8+ T cells, showing 
expression of inhibitory markers. (B) Median fluorescence intensity (MFI) of PD-1 and 
2B4 in gp33-tetramer+ CD8+ T cells over time. Symbols represent mean ± SEM of 3-4 
mice. Analyzed by linear regression. (C) Representative flow plots gated on gp33-
tetramer+ CD8+ T cells, showing expression of T-bet, Eomes, and PD-1. Numbers 
indicate the frequency of cells within the adjacent gate. (D) Ratio of T-bet MFI to Eomes 
MFI in gp33-tetramer+ CD8+ T cells over time. Symbols represent mean ± SEM of 3-4 
mice. Analyzed by linear regression.  
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Figure 4.4. Prf1-/- gp33-specific CD8+ T cells gradually lose effector function in the 
setting of ST2 blockade. 
Prf1-/- mice were infected with LCMV, treated every other day with α-ST2 antibody 
beginning on day 3 p.i., and assessed on days 8, 15, or 30 p.i. WT mice infected with 
LCMV and analyzed 30 days p.i. provided an LCMV-immune control. Top row, 
frequencies of CD8+ T cells specifically producing cytokine or externalizing CD107a in 
response to in vitro gp33 peptide stimulation. Bottom row, cytokine MFI of cytokine+ 
CD8+ T cells stimulated with gp33 peptide. Bars represent mean ± SEM of 3-4 mice. 
Prf1-/- α-ST2 groups were analyzed by one-way ANOVA; significance of Tukey’s post-
test comparing all groups is indicated. 
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Figure 4.5. Withdrawal of ST2 blockade does not reverse CD8+ T cell exhaustion. 
Prf1-/- mice were infected with LCMV and were either treated with α-ST2 antibody 
continuously (α-ST2) or were withdrawn (w/d) from α-ST2 treatment at day 15 p.i. and 
thereafter given isotype control antibody. Antibody treatments were administered every 
other day, beginning on day 3 p.i. All mice were assessed on day 30 p.i. N=3-4 
mice/group. Analyzed by Student’s two-tailed t-test. (A) Numbers of gp33-specific CD8+ 
T cells. (B) Frequencies of gp33-tetramer+ CD8+ T cells expressing Ki-67. (C) 
Representative histograms gated on gp33-tetramer+ CD8+ T cells, showing expression of 
PD-1. (D) Representative flow plots gated on gp33-tetramer+ CD8+ T cells, showing 
expression of Eomes and PD-1. Numbers indicate the frequency of cells within the 
adjacent gate. (E) Frequency and IFNγ MFI of CD8+ T cells specifically producing IFNγ in 
response to in vitro gp33 peptide stimulation. Bars represent mean ± SEM. 
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Figure 4.6. CD8+ T cell exhaustion in chronically-infected perforin-sufficient mice 
is largely independent of ST2. 
WT and Il1rl1-/- mice (n=6/group) were infected with LCMV Cl-13 and assessed on day 
15 p.i. An additional group of WT mice (n=4) was infected with LCMV Arm and analyzed 
on day 8 p.i. as a control. Analyzed by one-way ANOVA; significance of Tukey’s post-
test comparing all groups is indicated. (A) Numbers of effector CD44hiCD62Llo CD8+ T 
cells. (B) Numbers of gp33-specific CD8+ T cells. (C-E) Frequencies of gp33-tetramer+ 
CD8+ T cells expressing PD-1 (C), 2B4 (D), or Ki-67 (E). (F) Frequencies of Eomeshi PD-
1hi cells among gp33-tetramer+ CD8+ T cells. (G) Frequencies (top row) and cytokine 
MFI (bottom row) of CD8+ T cells specifically producing cytokine or externalizing 
CD107a in response to in vitro gp33 peptide stimulation. Bars represent mean ± SEM. 
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Figure 4.7. Reversal of exhaustion partially protects FHL2 mice from chronic 
weight loss. 
Prf1-/-Il1rl1-/- mice were infected with LCMV, weighed daily, and treated with 200 µg of 
either α-PD-L1 or isotype control antibodies every 3 days, beginning on day 15 p.i. 
Starting body weight was determined on day 0, and average weight did not differ 
significantly between the two groups from days 0 to 15 p.i. (not shown).   
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Figure 4.8. Model of the relationship between CD8+ T cell responsiveness and 
disease outcome in FHL mice. 
Throughout the duration of an antiviral response, CD8+ T cells are subject to various 
forms of negative regulation, indicated along the x-axis. Early on, mechanisms such as 
perforin-mediated pruning of APCs limits the accumulation of effector CD8+ T cells; at a 
later timepoints, other forms of restraint, such as exhaustion, arise. The y-axis 
represents the magnitude of inflammation elicited during the antiviral response. With 
increasing inflammation comes the potential for increasing immunopathology; if the 
severity of immunopathology escalates such that the organism cannot sustain life, it will 
cross the threshold for mortality. 
 
We propose that murine models involving LCMV infection can be represented by 
different trajectories through this plot. In the case of a WT mouse infected with LCMV 
Arm, there will be some degree of inflammation, but it will clear the infection and 
downregulate its immune response quickly, obviating the need to initiate exhaustion. 
Conversely, an LCMV Arm-infected Prf1-/- mouse will experience a high degree of 
inflammation due to perforin deficiency and cross the mortality threshold due to 
overwhelming immunopathology, also before reaching the point of exhaustion. However, 
modulation by ST2 blockade reduces early inflammation in Prf1-/- mice sufficiently to 
prolong survival, providing time for their CD8+ T cells to undergo exhaustion and 
enabling them to tolerate a chronic infection – similar to Cl-13-infected WT mice or Arm-
infected Stx11-/- mice.  
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CHAPTER 5: 
IL-10 distinguishes a unique population of activated, effector-like CD8+ T 
cells in murine acute liver inflammation 
 
Introduction 
 The liver stands out as one of the organs most heavily targeted by systemic 
inflammation in hemophagocytic syndromes. The majority of patients presenting with 
FHL or MAS manifest some degree of hepatic dysfunction, ranging from elevated 
transaminases and hepatomegaly to fulminant liver failure (Jordan et al., 2011). Indeed, 
liver failure in hemophagocytic syndrome is a well-recognized complication of the 
disease and can sometimes dominate the clinical presentation (Amin et al., 2013; Bihl et 
al., 2006; Canna and Behrens, 2012; Jordan et al., 2011). The factors contributing to 
liver damage in these cases are likely multifactorial. Elevated levels of inflammatory 
cytokines, such as TNFα, can mediate direct hepatotoxic effects (Schwabe and Brenner, 
2006). Coagulopathy arising from systemic inflammation, particularly disseminated 
intravascular coagulation, can be particular destructive in the small, tortuous vessels of 
the highly vascularized liver, easily leading to ischemia and hepatocyte death. Most 
notably, the liver is a site of extensive infiltration by inflammatory cells, particularly 
activated macrophages (including hemophagocytes) and lymphocytes. In addition to 
disrupting normal tissue architecture and causing congestive liver dysfunction, these 
cells release high levels of cytokines and immune effectors that can have significant 
detrimental effects on the surrounding hepatic tissue. 
To better understand the nature of hepatic inflammation in hemophagocytic 
syndrome, we focused on macrophage activation syndrome (MAS), a secondary form of 
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hemophagocytic syndrome in which liver dysfunction is one of the central features. MAS 
is a complication of rheumatologic disease, particularly in children. It is most commonly 
associated with pediatric autoimmune diseases such as systemic juvenile idiopathic 
arthritis (sJIA), systemic lupus erythematosus (SLE), and Kawasaki disease, as well as 
adult forms of these diseases such as adult-onset Still’s disease (Schulert and Grom, 
2014). Up to 17% of patients with sJIA develop overt MAS, although as many as a third 
harbor evidence of sub-clinical “occult” MAS; in many cases, distinguishing MAS from an 
active disease flare can be difficult (Behrens et al., 2007). Although there is considerable 
heterogeneity in the clinical features and pathophysiology of the underlying diseases, 
MAS itself closely resembles FHL in its clinical presentation, treatment, and severity 
(Canna and Behrens, 2012). While the initiating pathologic processes in MAS are likely 
different than in FHL, and probably reflect elements of the associated autoimmune 
disease, both forms of hemophagocytic syndrome are driven by a common theme of 
hyperactivated macrophages and lymphocytes leading to systemic inflammation 
(Weaver and Behrens, 2014). 
In this study, we used the murine model of MAS induced by Toll-like receptor 9 
(TLR9) stimulation (TLR9-MAS) to investigate liver-infiltrating immune cells (Behrens et 
al., 2011). This model relies on serial injections of the TLR9 agonist, CpG, to induce 
inflammation in wild-type mice that is reminiscent of MAS, complete with splenomegaly, 
hypercytokinemia, cytopenias, hyperferritinemia, and hepatitis. Analogous to the role of 
DAMPs in promoting inflammation in murine FHL, the TLR9-MAS model demonstrates 
that excessive signaling by PAMPs, in this case CpG, is also capable of driving systemic 
inflammation. We identified a large population of hepatic CD8+ T cells in TLR9-MAS 
mice that surprisingly produces both interleukin-10 (IL-10) and interferon-gamma (IFNγ). 
This subset bears little resemblance to previously described IL-10+ CD8+ suppressor T 
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cells. Instead, these cells arise independently of antigen stimulation and rely indirectly on 
IFNγ for their induction. Using extensive phenotypic and transcriptional analysis, we 
determined that these IL-10+ hepatic CD8+ T cells resemble activated, early effector 
CD8+ T cells, similar to those elicited by viral or intracellular bacterial pathogens. 
However, they also exhibit a particular signature of responsiveness to growth factors 
induced by hepatic damage. Thus, our study provides evidence that IL-10+ CD8+ T cells 
are a prominent immune cell subset at the site of liver injury in the context of systemic 
inflammatory disease. These findings may provide insight into the pathophysiology of 
hemophagocytic syndrome and suggest that future studies investigating inflammatory 
infiltrates in systemic inflammatory illnesses with liver dysfunction should include 
analysis of IL-10+ hepatic CD8+ T cells. 
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Results 
IL-10-producing CD8+ T cells are prominent among hepatic inflammatory infiltrates 
in murine hemophagocytic syndrome 
The TLR9-MAS murine model of hemophagocytic syndrome results in severe 
liver damage, as evidenced by hepatomegaly, marked lymphohistiocytic inflammatory 
infiltration, and lobular necrosis (Behrens et al., 2011). Using this well-characterized 
model as a foundation for studying mechanisms of hepatic damage during systemic 
inflammation, we first surveyed the principal immune cell populations induced by 
inflammation. Livers of CpG-treated TLR9-MAS mice demonstrated a mixed infiltrate 
with CD8+ T cell predominance (Figure 5.1A). This finding is strikingly similar to that of 
histologic analyses showing numerous CD8+ T cells in liver biopsies from FHL and MAS 
patients (Billiau et al., 2005; Chen et al., 2010). Given this consistency and the 
pathogenic role of CD8+ T cells in murine FHL (Jordan et al., 2004; Terrell and Jordan, 
2013), we decided to further characterize this intrahepatic CD8+ T cell pool. 
 Only a small fraction of splenic CD8+ T cells in TLR9-MAS mice are able to 
produce IFNγ, the primary cytokine driving inflammation in this model (Behrens et al., 
2011); in contrast, the majority of hepatic CD8+ T cells in these mice are IFNγ producers 
(Figure 5.1B). Surprisingly, a large proportion of these IFNγ+ hepatic CD8+ T cells also 
produced IL-10 (Figure 5.1B), an anti-inflammatory cytokine classically associated with 
CD4+ T regulatory (Treg) cells and the main negative regulator of inflammation in TLR9-
MAS mice (Behrens et al., 2011). Having confirmed that IL-10 is produced at the protein 
level, we then made use of IL-10 reporter mice, which report IL-10 transcription through 
the production of GFP and show excellent correlation between IL-10 protein and GFP 
expression (Figure 5.1C) (Kamanaka et al., 2006). We found that CpG induces 
substantial IL-10 production by CD8+ T cells and these cells are, in fact, the largest 
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population of IL-10 producers in the livers of TLR9-MAS mice (Figure 5.1D). 
Furthermore, numerous IL-10+ CD8+ T cells were also present in the livers of LCMV-
infected Prf1-/- mice, representing the murine model of FHL2 (Figure 5.1E). These data 
suggest that IL-10 production marks an atypical population of hepatic CD8+ T cells, and 
their localization to the liver in multiple models of hemophagocytic syndrome suggests 
the possibility of a connection between IL-10+ CD8+ T cells and severe hepatic 
inflammation. Thus, we decided to investigate these IL-10+ hepatic CD8+ T cells further. 
 
IL-10+ hepatic CD8+ T cells in TLR9-MAS mice are a unique population induced in 
an IFNγ-dependent, antigen-independent manner  
 Several populations of IL-10+ CD8+ T cells with suppressive function have been 
described previously (Bienvenu et al., 2005; Endharti et al., 2005; Liu et al., 2013b; Rifa'i 
et al., 2004; Xystrakis et al., 2004). These populations are characterized by distinct 
surface marker expression, antigen specificities, and mechanisms of suppression. To 
determine whether IL-10+ CD8+ T cells in the livers of TLR9-MAS mice resemble these 
CD8+ Treg cells, we first examined characteristic phenotypic markers of natural CD8+ 
Treg cells. However, unlike Foxp3+CD8+, CD122+CD8+, or Qa1-restricted CD8αα+ Treg 
cells (Bienvenu et al., 2005; Rifa'i et al., 2004; Tang et al., 2006; Xystrakis et al., 2004), 
IL-10/GFP+ CD8+ T cells in TLR9-MAS mice lacked expression of Foxp3 and were 
nearly all CD122- conventional CD8αβ+ T cells (Figures 5.2A-C). Inducible, antigen-
dependent CD8+ Treg populations expressing either CD11c or CD103 have also been 
described (Liu et al., 2013b; Vinay et al., 2009). Since a portion of IL-10+ hepatic CD8+ T 
cells in TLR9-MAS mice express CD11c (~25%) or CD103 (~50%) (data not shown), we 
next determined their reliance on antigen. For these studies, we used OT-I IL-10 reporter 
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mice, whose T cells express a transgenic Vβ5.1/5.2 T cell receptor (TCR) specific for the 
MHC class I-restricted SIINFEKL peptide of ovalbumin, that were treated with CpG but 
not exposed to ovalbumin. Notably, CpG induced similar frequencies of both total and 
Vβ5.1/5.2+ hepatic CD8+ T cells expressing IL-10/GFP in OT-I IL-10 reporter (OT-I) mice 
as in IL-10 reporter (WT) mice (Figure 5.2D). The total number of IL-10/GFP+ CD8+ T 
cells in the livers of OT-I mice was at least as high as in WT mice (Figure 5.2D), further 
demonstrating that substantial numbers of IL-10+ hepatic CD8+ T cells can be induced 
independent of antigen. Thus IL-10+ hepatic CD8+ T cells in TLR9-MAS mice are distinct 
from other IL-10-expressing CD8+ Treg populations that have previously been described. 
 We then asked whether these IL-10+ hepatic CD8+ T cells rely instead on 
cytokine-mediated activation, similar to populations of effector and memory CD8+ T cells 
that have been described (Berg et al., 2003; Freeman et al., 2012; Kambayashi et al., 
2003; Kohlmeier et al., 2010; Zhang et al., 1998). Since IFNγ plays a central role in the 
pathogenesis of TLR9-MAS (Behrens et al., 2011; Canna et al., 2013), we examined the 
livers of CpG-injected mice deficient in IFNγR. Ifngr-/- IL-10 reporter mice demonstrated a 
lower frequency of IL-10-producing cells among hepatic CD8+ T cells than did IL-10 
reporter mice (mean 45.6% vs. 25.0%, respectively), resulting in a decrement of 50% in 
total frequency (Figure 5.2E). To determine whether this partial dependence on IFNγ 
was CD8+ T cell-intrinsic or -extrinsic, we generated BM chimeras using donor cells from 
IL-10 reporter (WT) mice, Ifngr-/- IL-10 reporter (Ifngr-/-) mice, or both. Consistent with 
data in the global IFNγR knockout (Figure 5.2E), mice receiving Ifngr-/- BM showed a 
lower frequency of IL-10/GFP+ hepatic CD8+ T cells induced by CpG than mice receiving 
WT BM (Figure 5.2F). However, equivalent frequencies of WT and Ifngr-/- hepatic CD8+ T 
cells produced IL-10 in response to CpG stimulation in mixed BM chimeras (Figure 
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5.2F), demonstrating that the partial dependence of IL-10+ hepatic CD8+ T cells on IFNγ 
is CD8+ T cell-extrinsic. Thus, IL-10+ CD8+ T cells in the livers of TLR9-MAS mice rely 
largely on indirect effects of IFNγ signaling, rather than antigen, for their induction. 
Together, these data suggest that this TLR9-induced IL-10+ hepatic CD8+ T cell 
population does not resemble previously described populations of IL-10-producing CD8+ 
T cells and may therefore represent a unique subset of CD8+ T cells. 
 
IL-10+ hepatic CD8+ T cells have an activated phenotype consistent with terminally 
differentiated effectors 
 To further characterize this unique population of IL-10-producing CD8+ T cells, 
we sorted IL-10/GFP+ and IL-10/GFP- CD8+ T cells from the livers of TLR9-MAS IL-10 
reporter mice and examined their surface phenotype. IL-10/GFP+ hepatic CD8+ T cells 
were uniformly CD44+CD62L-CD69+, suggesting they are recently activated effector cells 
(Figures 5.3A-B). Furthermore, these cells had low expression of CD127 and a high 
proportion of them expressed KLRG1, consistent with terminally differentiated effectors 
(Figures 5.3A-B). In contrast, IL-10/GFP- CD8+ T cells were a more heterogeneous 
population, composed of CD44- naïve cells, CD44+CD62L+ memory cells, CD44+CD62L-
CD127+KLRG1- memory precursors, and a minority of terminally differentiated effectors 
(Figures 5.3A-B). Among antigen-experienced (CD44+) hepatic CD8+ T cells, those 
producing IL-10 had higher expression of the key transcription factor T-bet, which is 
known to drive terminal effector differentiation (Joshi et al., 2007), compared to their IL-
10- counterparts (Figure 5.3C). IL-10/GFP+ CD8+ T cells also demonstrated relative 
upregulation of Eomesodermin, which is induced shortly after T cell activation (Figure 
5.3C) (Pearce et al., 2003). Interestingly, IL-10/GFP+ hepatic CD8+ T cells tended to 
have higher expression of both T-bet and Eomesodermin than control bona fide effector 
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CD8+ T cells from LCMV-infected mice (Figure 5.3C). This difference may be a reflection 
of the different organs and inflammatory inducers used in these two systems, but may 
also identify a characteristic distinguishing IL-10+ hepatic CD8+ T cells from conventional 
effector CD8+ T cell populations. 
 
IL-10+ hepatic CD8+ T cells demonstrate a high turnover rate 
 The massive increase in hepatic CD8+ T cell numbers in TLR9-MAS mice (Figure 
5.1A) suggested that inflammation induced a rapid expansion and/or influx of CD8+ T 
cells into the liver. Consistent with their effector phenotype, we found that >90% of 
CD44+ IL-10/GFP+ hepatic CD8+ T cells were Ki-67+, suggesting a high degree of 
proliferation similar to control effector CD8+ T cells (Figure 5.4A). The majority of IL-
10/GFP- hepatic CD8+ T cells did not stain with Ki-67, and even among those expressing 
CD44, the frequency of proliferating cells was consistently lower than among their IL-10-
producing counterparts (Figure 5.4A). These data highlight a functional difference 
between the IL-10+ and IL-10- hepatic CD8+ T cell subsets and again suggest that the IL-
10+ population is more activated. 
 Accordingly, one would expect highly proliferative, terminally-differentiated 
effector CD8+ T cells to also exhibit enhanced susceptibility to cell death. We found that 
the IL-10/GFP+ hepatic CD8+ T cells had markedly decreased viability in vitro regardless 
of culture conditions. The frequency of live IL-10/GFP+ hepatic CD8+ T cells was 
consistently 40.9-59.1% lower than that of their IL-10/GFP- counterparts (Figure 5.4B). In 
contrast to naïve splenic CD8+ T cells and IL-10/GFP- hepatic CD8+ T cells, IL-10/GFP+ 
hepatic CD8+ T cells showed reduced viability after as little as six hours in culture 
(Figure 5.4C). The addition of bone marrow-derived dendritic cells (BMDC) activated 
with CpG, TCR stimulation, exogenous cytokines, or serum from a TLR9-MAS mouse 
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failed to rescue the viability of IL-10/GFP+ CD8+ T cells (Figures 5.4B-C). The strikingly 
differential survival of IL-10+ and IL-10- subsets of hepatic CD8+ T cells treated with the 
same experimental conditions suggest that IL-10+ CD8+ T cells are intrinsically more 
susceptible to cell death. Together, these findings show that IL-10+ hepatic CD8+ T cells 
display a high degree of turnover resembling that of short-lived effector cells. 
 
IL-10+ hepatic CD8+ T cells are transcriptionally distinct from their IL-10- 
counterparts and are induced independently of ST2 
Because the poor viability of IL-10+ hepatic CD8+ T cells precluded in vitro 
functional studies, we conducted transcriptional analysis of these cells immediately after 
harvesting them from TLR9-MAS IL-10 reporter mice. We performed genome-wide 
microarray studies on mRNA purified from four biological pairs of IL-10+ and IL-10- 
hepatic CD44+CD8+ T cells. Unsupervised clustering analysis of the gene expression 
data provided validation that these two populations are indeed distinguishable 
transcriptionally, as all IL-10+ samples clustered separately from IL-10- samples (Figure 
5.5A). We then performed statistical analysis to identify genes that were differentially 
regulated between the two populations. Using a false discovery rate of 20% and a fold-
change cut-off of at least 1.5X, we found 178 genes significantly increased and 204 
genes significantly decreased in IL-10+ cells compared to IL-10- cells. Importantly, we 
found that Il10 was the gene most upregulated in the IL-10+ population as compared to 
the IL-10- cells, thereby validating our sorting purity and analysis methods (Figure 5.5B).  
Interestingly, Il1rl1, the gene encoding ST2, was among the top differentially 
upregulated genes in IL-10+ CD8+ T cells relative to IL-10- CD8+ T cells (Figure 5.5B). 
Given the importance of ST2 in the induction of effector CD8+ T cells in murine FHL (see 
Chapter 3), we wondered whether IL-33/ST2 signaling could similarly promote the 
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induction of this effector-like IL-10+ hepatic CD8+ T cell population in TLR9-MAS mice. 
However, TLR9-MAS mice treated with α-ST2 antibody showed no difference in either 
the frequency of IL-10/GFP+ cells among hepatic CD8+ T cells or the total numbers of IL-
10/GFP+ CD8+ T cells in the liver, compared to TLR9-MAS mice treated with an isotype 
control antibody (Figures 5.5C-D). Thus, while the Il1rl1 upregulation noted in our IL-10+ 
hepatic CD8+ T cell population is reminiscent of effector CD8+ T cells in other settings 
(Bonilla et al., 2012; Yang et al., 2011), signaling through ST2 is dispensable for their 
induction. 
Consistent with our phenotypic data (Figure 5.3), further analysis of differentially 
expressed genes revealed hallmarks characteristic of effector CD8+ T cells among the 
IL-10-producing population. Expression of Furin, which is induced upon TCR stimulation 
(Pesu et al., 2006), was highly upregulated in IL-10+ hepatic CD8+ T cells relative to their 
IL-10- counterparts (Figure 5.5B). The most downregulated genes were notable for 
several chemokine receptors (S1pr1, Cxcr5, Ccr7) and other genes typically expressed 
at low levels in effector CD8+ T cells (Il7r, Actn1) (Figure 5.5B) (Benechet et al., 2016; 
Jung et al., 2010; Wherry et al., 2007). These data suggest that IL-10+ hepatic CD8+ T 
cells are programmed to circulate through non-lymphoid tissues, consistent with their 
accumulation in the liver. 
The entire list of differentially expressed genes was then submitted to Ingenuity 
Pathway Analysis (IPA) to identify putative upstream regulators (Tables 5.1 and 5.2) and 
downstream functional biologic pathways. Predicted activation of the retinoic acid 
receptor alpha (RARA) pathway further supports the effector differentiation status, as 
well as the liver-homing capability, of our cells (Table 5.1) (Allie et al., 2013; Guo et al., 
2014). A number of upregulated genes were regulators of cell cycle (e.g. Ccnb1, Figure 
5B), as were putative upstream regulators such as FOXM1, MYC, S100A6, CCND1, 
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MAPK1 (predicted activation, Table 5.1) and TP53, CDKN2A, CDKN1A, RBL1 
(predicted inhibition, Table 5.2), indicative of highly proliferative cells and thus 
corroborating our results in Figure 5.4A. Consistent with the reduced viability of IL-10-
producing cells (Figures 5.4B-C), downstream analysis of cell death pathways 
demonstrated that a significant number of genes associated with increased T cell 
apoptosis were differentially expressed in IL-10+ cells, including Fasl (upregulated 1.535-
fold) and Bcl2 (downregulated 1.923 fold). IPA predicted increased T cell apoptosis with 
a p-value of 4.6 x 10-5 and a z-score of 1.98, suggesting apoptosis is likely enhanced in 
IL-10+ hepatic CD8+ T cells. The predicted activation of E2F, which promotes Fas-
mediated lymphocyte apoptosis (Cao et al., 2004), is further consistent with this 
hypothesis (Table 5.1). Interestingly, several type I and III IFN-dependent pathways 
were predicted to be inhibited in IL-10+ CD8+ T cells, including IRF7, IRF3, IFNA2, 
IFNAR1, DDX58, IRF5, and IFNL1 (Table 5.2). Although type I IFNs are important for 
inducing effector differentiation and proliferation of CD8+ T cells in certain contexts, IL-12 
can provide equivalent priming support in others (Keppler et al., 2012). Thus, these 
findings reflect relative independence of IL-10+ T cells from type I/III IFN signaling and 
may suggest reliance instead on IL-12, which has a dominant pathogenic role in TLR9-
MAS (Canna et al., 2013). 
 
The transcriptional signature of IL-10+ hepatic CD8+ T cells is most similar to that 
of day 6 effector CD8+ T cells but shows responsiveness to liver growth factors 
The gene expression results thus far point to an effector-like classification for IL-
10+ hepatic CD8+ T cells, but we wanted to compare them to a known standard. The 
Immunological Genome Project (ImmGen) has generated data on CD8+ T cell subtypes 
by isolating adoptively transferred OT-I cells from Listeria-OVA-infected mice at different 
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time points post-infection (Best et al., 2013). We performed clustering analysis to 
compare the transcriptional profiles of our IL-10+ and IL-10- CD8+ T cells to these 
ImmGen CD8+ T cell subsets, using the top 500 genes able to differentiate among 
ImmGen subsets. Remarkably, the IL-10+ hepatic CD8+ T cells clustered closest to the 
Day 6 ImmGen subset, while the IL-10- hepatic CD8+ T cells were most similar to naïve 
CD8+ T cells (Figure 5.6A). These data provide further evidence that IL-10 marks a 
distinct CD8+ T cell population in the liver that best resembles early effectors. 
Furthermore, when we examined Il10 expression in publically available datasets 
generated from C57BL/6 mice infected with LCMV (Doering et al., 2012), we found peak 
expression among LCMV GP33-specific CD8+ T cells 6 days post-infection (Figure 
5.6B).  
However, IL-10+ hepatic CD8+ T cells were not merely identical to conventional 
effector cells. Strikingly, their transcriptional profile showed hallmarks of activation by 
hepatocyte growth factor (HGF) and vascular endothelial growth factor (VEGF) (Table 
5.1, Figure 5.6C), two growth factors highly induced upon hepatic injury (DeLeve, 2013). 
HGF enhances T cell adhesion and promotes leukocyte migration to the liver (Adams et 
al., 1994; Komarowska et al., 2015). VEGF is important for the maintenance of liver 
sinusoidal endothelial cells, which are specially equipped to recruit lymphocytes to the 
liver (Lalor et al., 2006). Thus, the predicted responsiveness of IL-10+ hepatic CD8+ T 
cells to HGF and VEGF provides evidence that these cells may specifically home to 
injured liver and undergo transcriptional reprogramming there. 
Taken together, these data demonstrate that IL-10+ hepatic CD8+ T cells 
represent a unique subset of highly activated, antigen-independent, early effector cells 
induced by systemic inflammation to accumulate within damaged liver, with the potential 
to contribute to pathogenesis.  
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Discussion 
 This study provides new insight into the immune cell subsets associated with 
inflammatory liver damage. In particular, we identified CD8+ T cells that paradoxically 
produce both IFNγ and IL-10 as a major population evident at the site of hepatic 
destruction. Despite their lack of requirement for cognate antigen stimulation, these cells 
have initiated a transcriptional program similar to that of early effector CD8+ T cells. They 
are highly proliferative, yet also exhibit greater susceptibility to cell death. Furthermore, 
they appear responsive to HGF and VEGF, suggesting they are uniquely primed to 
migrate to the liver. Overall, these findings highlight IL-10+ hepatic CD8+ T cells as an 
intriguing new population of liver-infiltrating cells that should be considered in future 
studies of immune-mediated liver injury. 
 Although production of IL-10 is not classically associated with CD8+ T cells, 
several subsets of both natural and induced IL-10+ CD8+ Treg cells have been described 
(Bienvenu et al., 2005; Endharti et al., 2005; Liu et al., 2013b; Xystrakis et al., 2004). 
Surprisingly, the IL-10-producing CD8+ T cells seen in the livers of TLR9-MAS mice did 
not resemble any of these CD8+ Treg populations, either in phenotype or antigen 
dependence (Figure 5.2). Consistent with this distinction, their transcriptional signature 
was inflammatory, rather than regulatory (Figure 5.6), suggesting that not all IL-10-
producing CD8+ T cells may be suppressive. While the low viability of our IL-10+ CD8+ T 
cells precluded in vitro functional analysis, and thus a definitive assessment of 
suppressive function, this susceptibility to cell death is itself uncharacteristic of CD8+ 
Treg cells (Hahn et al., 2005), making it even less likely that this population would 
mediate an anti-inflammatory program. Furthermore, IL-10 does not always inhibit 
inflammation, as direct stimulatory effects of IL-10 on CD8+ T cells have been described 
in specific situations (Freeman et al., 2012; Groux et al., 1998).  
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 There is some evidence to suggest that IL-10 production is part of the normal 
CD8+ T cell effector program and may act as a self-regulatory mechanism by fine-tuning 
the balance of pro- and anti-inflammatory cytokines produced in the context of infections 
(Cyktor et al., 2013; Hu et al., 2013; Spender et al., 1998; Sun et al., 2011; Sun et al., 
2009; Trandem et al., 2011). This hypothesis is supported by the findings that our IL-10+ 
hepatic CD8+ T cells most closely resemble day 6 effectors and that LCMV-specific 
CD8+ T cells briefly upregulate IL-10 transcription 6 days post-infection, around the peak 
of the anti-viral response (Figure 5.6). However, this study provides, to our knowledge, 
the first description of the induction of IL-10 production by CD8+ T cells in an antigen-
independent manner. We found that IL-10+ hepatic CD8+ T cells induced by CpG 
inflammation were partially, but indirectly, dependent on IFNγ (Figure 5.2). Effector CD8+ 
T cells can be activated by cytokine stimulation to produce IFNγ, independently of 
cognate antigen recognition (Berg et al., 2003; Freeman et al., 2012); however, the 
induction of IL-10 production in such cells has not been described. The results of the 
present study therefore suggest that antigen-independent CD8+ T cell activation leading 
to the production of both pro- and anti-inflammatory cytokines is an underappreciated 
part of the innate immune response and may have important physiologic implications for 
bystander cells in the vicinity (Bowen et al., 2002). 
 The liver is one of the primary organs affected by hemophagocytic syndromes 
(Canna and Behrens, 2012; Jordan et al., 2011) and is also a site at which activated, 
apoptotic T cells accumulate in a variety of inflammatory murine models (Belz et al., 
1998; Huang et al., 1994; Wack et al., 1997). Work by the Crispe lab and others has 
demonstrated the ability of the liver to selectively retain activated CD8+ T cells, whether 
through enhanced expression of ICAM-1 and other adhesion molecules by liver 
sinusoidal endothelial cells or the low flow rate and tortuosity of hepatic circulation (John 
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and Crispe, 2004; Mehal et al., 1999). The high rate of cell death seen among these 
intrahepatic CD8+ T cells has led to the hypothesis that the liver acts as a “killing field” or 
death trap for activated T cells. Alternatively, activated CD8+ T cells that are already 
programmed to die may migrate to the liver to undergo apoptosis, implying that the liver 
is actually a “graveyard” or disposal site for moribund T cells (Crispe et al., 2000; Park et 
al., 2002). Our finding that IL-10+ hepatic CD8+ T cells are highly activated yet have 
extremely low viability (Figure 5.4B), as well as a transcriptional signature suggesting 
activation of T cell apoptosis pathways, could be consistent with either model. 
Regardless of the mechanism, there are significant implications of such an 
accumulation of potently activated cells in the liver. Any influx of FasL-expressing cells to 
the liver, such as those described here, poses a great danger to hepatocytes, which 
constitutively express Fas and are thus highly susceptible to apoptosis (Malhi et al., 
2010; Ogasawara et al., 1993). In murine models of sepsis or systemic T cell activation, 
CD8+ T cells migrating to the liver have increased expression of FasL and mediate Fas-
dependent hepatotoxicity (Kennedy et al., 2001; Wesche-Soldato et al., 2007); Fas/FasL 
signaling has also been implicated in the liver damage observed in murine FHL 
(Chiossone et al., 2012). The high expression of FasL on our IL-10+ CD8+ T cells raises 
the possibility that a similar mechanism may occur in TLR9-MAS. Furthermore, FasL-
mediated apoptosis of IL-10+ CD8+ T cells themselves may actually be pathogenic, as 
Kupffer cell phagocytosis of apoptotic bodies induces their upregulation of death 
receptor ligands such as TNFα, TRAIL, and FasL (Canbay et al., 2003). It thus seems 
likely that CD8+ T cells activated throughout the body independently of antigen have 
significant potential to cause collateral damage to liver tissue.  
 In summary, we have identified and characterized a subset of innately-induced, 
effector-like IL-10+ CD8+ T cells that are associated with liver inflammation. Further study 
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will not only be important for understanding the role of this particular IL-10+ hepatic CD8+ 
T cell subset, but may also offer insights that will enable us to dissect mechanisms of 
inflammatory liver damage.  
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Tables 
Table 5.1: Upstream pathway analysis, predicted activated regulators. 
Upstream 
Regulator Molecule Type 
Activation 
z-score 
p-value of 
overlap 
ESR1 ligand-dependent nuclear receptor 5.435 6.87E-12 
PTGER2 g-protein coupled receptor 5.222 2.52E-37 
CSF2 cytokine 4.083 4.99E-31 
FOXM1 transcription regulator 3.794 4.92E-13 
TBX2 transcription regulator 3.769 7.00E-15 
HGF growth factor 3.535 5.80E-17 
MYC transcription regulator 3.529 1.06E-06 
Vegf group (growth factor) 3.139 1.78E-18 
ACKR2 g-protein coupled receptor 3.000 1.95E-08 
TRIM24 transcription regulator 2.985 1.41E-05 
MED1 transcription regulator 2.945 7.99E-06 
MITF transcription regulator 2.889 6.30E-12 
S100A6 transporter 2.828 4.59E-08 
RARA ligand-dependent nuclear receptor 2.820 6.56E-13 
AR ligand-dependent nuclear receptor 2.589 5.91E-12 
CCND1 transcription regulator 2.496 2.16E-24 
AHR ligand-dependent nuclear receptor 2.440 2.87E-05 
NKX2-3 transcription regulator 2.324 6.66E-06 
E2f group (transcription regulator) 2.204 4.90E-10 
MAPK1 Kinase 2.144 3.98E-06 
TRAF2 enzyme 2.105 2.30E-07 
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Table 5.2: Upstream pathway analysis, predicted inhibited regulators. 
Upstream 
Regulator Molecule Type 
Activation z-
score 
p-value of 
overlap 
NUPR1 transcription regulator -5.864 4.50E-17 
TCF3 transcription regulator -4.359 5.46E-13 
TP53 transcription regulator -3.764 2.30E-25 
KDM5B transcription regulator -3.733 2.86E-07 
IRF7 transcription regulator -3.533 4.59E-09 
IRF3 transcription regulator -3.412 3.79E-08 
CDKN2A transcription regulator -3.300 4.56E-07 
IFNA2 cytokine -3.193 3.85E-12 
IFNAR1 transmembrane receptor -3.090 9.00E-10 
CDKN1A Kinase -2.715 3.89E-23 
TGM2 enzyme -2.688 3.52E-07 
DDX58 enzyme -2.608 2.46E-05 
BACH2 transcription regulator -2.607 7.22E-06 
IRF5 transcription regulator -2.353 9.86E-07 
SMARCE1 transcription regulator -2.236 3.24E-05 
DYRK1A Kinase -2.224 4.25E-05 
RBL1 transcription regulator -2.200 4.21E-05 
TLR9 transmembrane receptor -2.193 5.46E-09 
STAT5A transcription regulator -2.081 2.32E-05 
IFNL1 cytokine -2.030 6.96E-07 
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Figures 
 
Figure 5.1. IL-10-producing CD8+ T cells are prominent among hepatic 
inflammatory infiltrates in murine hemophagocytic syndrome. 
(A) Total numbers of liver lymphocytes in control (PBS-treated) or TLR9-MAS (CpG-
treated) WT mice. N=3-4 mice/treatment group, data are pooled from 2 independent 
experiments. (B) Cytokine production capacity of hepatic CD8+ T cells from TLR9-MAS 
mice. Histograms are gated on total live CD8+ T cells (left) or IFNγ+ CD8+ T cells (right). 
Unstimulated CD8+ T cells are shown in solid gray histograms for comparison. 
Representative of n=3 mice. (C) Flow plots showing correlation between production of 
IL-10 protein, stained with PE-conjugated anti-IL-10 antibody, and GFP expression in 
sorted IL-10/GFP+ and IL-10/GFP- hepatic CD8+ T cell populations from TLR9-MAS IL-
10 reporter mice. (D) Representative flow plots of liver leukocytes isolated from PBS- or 
CpG-injected IL-10 reporter mice, gated on TCRβ+CD8+CD4- cells. Numbers indicate 
frequency of IL-10/GFP+ cells among CD8+ T cells. Summary data for total numbers of 
IL-10/GFP+ cells in livers of PBS- and CpG-injected mice are shown. N=3-4 
mice/treatment group, data are pooled from 2 independent experiments. (E) Numbers of 
IL-10/GFP+ hepatic CD8+ T cells in uninfected (Uninf) or LCMV-infected (Inf) Prf1-/- IL-10 
reporter mice. N=2-6 mice/group. For (A) and (D), cell populations within TLR9-MAS 
mice were analyzed by one-way ANOVA; significance of Dunnett’s post-test comparing 
CD8+ T cells to all other groups is indicated. Experiments shown in (A) and (D) were 
performed by Scott Canna; and in (E), by Lehn Weaver.  
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Figure 5.2. IL-10+ hepatic CD8+ T cells in TLR9-MAS mice are a unique population 
induced in an IFNγ-dependent, antigen-independent manner. 
A-C) Representative flow plots of live hepatic CD8+ T cells from TLR9-MAS IL-10 
reporter mice. Numbers indicate frequency of cells within the gate. (A) FACS-purified IL-
10/GFP+ cells stained for surface CD25 and intracellular Foxp3 expression. Splenic 
CD4+ T cells from an untreated C57BL/6 mouse are shown for comparison. N=2 
mice/group, data are representative of 2 independent experiments. (B) Flow plot gated 
on IL-10/GFP+ hepatic CD8+ T cells, showing surface staining of CD122. Representative 
of n=4 mice. (C) Flow plot gated on IL-10/GFP+ hepatic CD8+ T cells, showing surface 
staining of CD8α and CD8β. Representative of n=2 mice. (D) IL-10 reporter mice with 
OT-I transgenic TCR (OT-I) or without (WT) received either PBS or CpG to induce 
TLR9-MAS, without exposure to ovalbumin. Frequency and number of total and 
Vβ5.1/5.2+ IL-10/GFP+ hepatic CD8+ T cells are shown. N=2-5 mice/group, data are 
representative of 2 independent experiments. Analyzed by unpaired Student’s t-test. (E) 
Frequency of IL-10/GFP-expressing hepatic CD8+ T cells in IL-10 reporter mice either 
sufficient for IFNΓR (WT) or deficient (Ifngr-/-). N=2-5 mice/group, data pooled from 2 
independent experiments. Analyzed by unpaired Student’s t-test. (F) BM chimeras 
reconstituted with cells from IL-10 reporter donors (WT), Ifngr-/- IL-10 reporter donors 
(Ifngr-/-), or a mixture of both (WT / Ifngr-/-) received either PBS or CpG to induce TLR9-
MAS. Frequencies of IL-10/GFP+ hepatic CD8+ T cells among WT cells (circles) and 
Ifngr-/- cells (triangles) are shown. N=2-5 mice/group, data are representative of 4 
independent experiments. Analyzed by unpaired Student’s t-test (WT CpG vs. Ifngr-/- 
CpG; WT CpG vs. mixWT CpG) or paired Student’s t-test (mixWT CpG vs. mixIfngr-/- 
CpG). n.s., not significant. Experiments shown in (C, E, F) were performed by Scott 
Canna. 
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Figure 5.3. IL-10+ hepatic CD8+ T cells have an activated phenotype consistent 
with terminally differentiated effectors. 
Phenotype of hepatic CD8+ T cells from TLR9-MAS IL-10 reporter mice. (A) 
Representative histograms showing expression of surface markers differentiating naïve, 
effector, and memory populations. Plots are gated on CD8+ T cells, either in total (for 
PBS conditions) or IL-10/GFP- and IL-10/GFP+ subsets (for CpG conditions). (B) 
Summary of data as shown in (A). N=4 mice/group, either pooled from 2 independent 
experiments (CD44, CD62L) or representative of 2 independent experiments (CD69, 
KLRG1, CD127). (C) Representative histograms and summary data for T-bet and 
Eomesodermin expression. Plots are gated on CD44+CD8+ T cells. Naïve and effector 
splenic CD8+ T cells are included for comparison. N=4 paired samples per group. Data 
are representative of 2 independent experiments. Analyzed by paired Student’s t-test. 
Scott Canna contributed to data shown in (A, B). 
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Figure 5.4. IL-10+ hepatic CD8+ T cells demonstrate a high turnover rate. 
(A) Frequency of Ki-67-expressing hepatic CD8+ T cells among IL-10/GFP- and IL-
10/GFP+ subsets, isolated from TLR9-MAS IL-10 reporter mice. Naïve and effector 
splenic CD8+ T cells are included for comparison. N=4 paired samples per group. Data 
are representative of 2 independent experiments. Analyzed by paired Student’s t-test. 
(B) Viability of live-sorted IL-10/GFP+ or IL-10/GFP- hepatic CD8+ T cells after in vitro 
culture with or without BMDC and CpG. N=4 paired samples/group, data are pooled from 
3 independent experiments. (C) Viability timecourse of live-sorted IL-10/GFP+ or IL-
10/GFP- hepatic CD8+ T cells, or naïve splenic CD8+ T cells.  
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Figure 5.5. IL-10+ hepatic CD8+ T cells are transcriptionally distinct from their IL-10- 
counterparts and are induced independently of ST2. 
(A-B) Gene expression in four biologically paired samples of IL-10+ and IL-10- hepatic 
CD44+CD8+ T cells from TLR9-MAS mice was analyzed by microarray. (A) Hierarchical 
clustering analysis of IL-10+ and IL-10- hepatic CD8+ T cell replicates. (B) Heatmap 
depicting the top 10 genes most differentially upregulated or downregulated in IL-10+ vs. 
IL-10- cells. Colors indicate the number of standard deviations from the mean intensity 
for a given gene. Paired samples correspond to the same columns within each group. 
(C-D) TLR9-MAS mice received either α-ST2 or isotype control antibody during MAS 
induction and were analyzed for the frequency (C) and number (D) of hepatic CD8+ T 
cells expressing IL-10/GFP. N=5 mice/group. Not significant by Student’s t-test. 
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Figure 5.6. The transcriptional signature of IL-10+ hepatic CD8+ T cells is most 
similar to that of day 6 effector CD8+ T cells but shows responsiveness to liver 
growth factors. 
(A) Hierarchical clustering analysis comparing IL-10+ and IL-10- hepatic CD8+ T cell 
subsets (rows labeled in purple) to ImmGen CD8+ T cell subsets (rows labeled in 
white/turquoise), performed by John Tobias. (B) Expression of Il10 from splenic naïve 
and LCMV GP33-specific CD8+ T cells isolated at 6, 8, 15, and 30 days post-infection 
with LCMV-Armstrong. Data from GEO# GSE41867. Analyzed by 1-way ANOVA; 
significance of Dunnett’s post-tests comparing D6 to all other groups are indicated. (C) 
Representation of HGF and VEGF networks, showing differential expression of 
downstream targets in IL-10+ cells and predicted activation state of upstream regulators.  
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CHAPTER 6: 
Discussion and future directions 
 
 The work presented in this dissertation investigates the interaction of activated 
CD8+ T cells arising in the context of systemic inflammation with their surrounding 
environment, both in their response to antigen-independent cues and their contribution 
to the cytokine storm. We have shown that the IL-33/ST2 pathway plays a key role in 
amplifying inflammation above the threshold for fatal disease in FHL2 mice. ST2 
intrinsically promotes LCMV-specific CD8+ and CD4+ T cell proliferation and potentiates 
IFNγ production, thereby raising systemic quantities of IFNγ to lethal levels. Blockade of 
ST2 signaling provides therapeutic benefit in murine FHL by acutely dampening the 
antiviral T cell response, which prolongs the survival of the mice and thus enables CD8+ 
T cell exhaustion to arise and mediate long-term protection from morbidity. In a different 
model of hemophagocytic syndrome, TLR9-MAS, a unique population of effector-like IL-
10-producing CD8+ T cells arises independently of antigen stimulation and accumulates 
within damaged liver. These studies provide new insight into the role of CD8+ T cells in 
hemophagocytic syndromes, but several important questions remain. 
 
The source of IL-33 in FHL mice  
 In Chapter 2, we showed that FHL2 mice have increased splenic expression of 
IL-33 compared to LCMV-infected WT mice, but the precise cellular source of this IL-33 
remains unclear. The spleen represents a major target organ of FHL and is populated by 
fibroblastic reticular cells (FRC) constitutively expressing high levels of IL-33 (Pichery et 
al., 2012). IL-33 expression in endothelial cells is constitutive in humans but inducible in 
mice: inflammatory stimuli such as LPS are required to upregulate IL-33 in endothelial 
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cells of the liver and throughout the vascular tree (Pichery et al., 2012). Given the 
prominent vascular leakage evident in other models of LCMV-induced CD8+ T cell-
mediated immunopathology (Frebel et al., 2012), and the susceptibility of endothelial 
cells to immune-mediate cell death, it is possible that endothelial cells comprise a major 
subset of cells dying and releasing IL-33 in murine FHL. Generation of IL-33-floxed Prf1-
/- mice and crosses to various Cre recombinase mice (e.g. Ccl19-Cre for FRC, Tek-Cre 
for endothelial cells) may provide greater resolution as to which sources of IL-33 are 
most important in this model. 
Furthermore, the precise triggers resulting in release of IL-33 in murine FHL2 are 
unknown. While the majority of evidence demonstrates that IL-33 is primarily released by 
necrotic cells, there is a burgeoning body of literature suggesting that living cells may 
also secrete IL-33 through an alternative pathway. Similar to IL-33, HMGB1 lacks a 
signal peptide but is secreted by activated monocytes and macrophages via a non-
classical mechanism (Gardella et al., 2002). Studies have demonstrated that living 
fibroblasts release IL-33 upon mechanical stress (Kakkar et al., 2012). Additionally, 
epithelial cells are capable of releasing IL-33 in response to extracellular ATP (Kouzaki 
et al., 2011). It is therefore possible that cellular stressors such as active LCMV infection 
or oxidative stress could induce significant levels of IL-33 to be released by non-dying 
cells. Or perhaps the massive influx of cells into the liver or spleen stresses the tensile 
capacity of the capsule of these organs, causing mechanical force to be transmitted 
through the tissue and culminate in IL-33 release. It would therefore be instructive to 
determine if necrosis is truly required for the disease-promoting effects of IL-33/ST2 in 
FHL2 mice. This could be accomplished through pharmacologic inhibition, via in vivo 
administration of necrostatin-1, an inhibitor of the kinase RIPK1, which is required for 
necroptosis (Degterev et al., 2008). Alternatively, because IL-33 expression in non-
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hematopoietic cells is sufficient to induce CD8+ T cell activation during LCMV infection 
(Bonilla et al., 2012), we could generate bone marrow chimeras by transferring Prf1-/- BM 
into irradiated RIPK1-kinase-dead hosts to determine whether the disease phenotype in 
FHL mice is dependent on necrosis-mediated IL-33 release (Berger et al., 2014).  
If necrosis is indeed required to promote FHL pathogenesis, it will be important to 
identify the primary inducer of necrotic cell death in this model. Given the massive influx 
of inflammatory cells into the liver and other organs, including activated macrophages 
and other phagocytes, it is possible that reactive oxygen species (ROS) generated as 
part of the oxidative burst induce necrosis. Future studies could investigate this 
possibility by using an inhibitor of NADPH oxidase, the large enzymatic complex upon 
which activated macrophages and other phagocytes rely to generate ROS for their 
respiratory burst, in LCMV-infected Prf1-/- mice. Alternatively, a genetic approach, such 
as crossing Prf1-/- mice to Cybb-/- mice, which lack a central component of the NADPH 
oxidase complex, could be used (Pollock et al., 1995). ROS can also derive from 
mitochondria, as in the case of TNFα- or ischemia-mediated necrosis (Zong and 
Thompson, 2006). To confirm a role for mitochondria-derived ROS, we can breed Prf1-/- 
mice to MCAT mice, which overexpress catalase in the mitochondria and thus have 
reduced mitochondrial ROS (Schriner et al., 2005). We can also probe the role of 
ischemia in inducing IL-33 release by crossing Prf1-/- mice with mice that are deficient in 
cyclophilin D (CyP-D). CyP-D is a component of the mitochondrial permeability transition 
pore, which forms in response to ischemic injury and initiates necrotic death; thus, CyP-
D-deficient mice demonstrate resistance to necrotic (but not apoptotic) cell death 
resulting from ischemia (Nakagawa et al., 2005). 
The fact that extracellular IL-33 is present in sufficient quantities to robustly 
activate CD8+ T cells in LCMV-infected WT mice (Bonilla et al., 2012), as well as in 
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FHL2 mice, makes it tempting to speculate that viral infection could be the proximal 
cause of necrotic death leading to IL-33 release – particularly since LCMV can directly 
infect epithelial cells, fibroblastic reticular cells, and other cellular sources of IL-33. 
However, LCMV is generally considered to be a noncytopathic virus (Borrow and Zajac, 
1997). This assumption is based on in vitro studies showing minimal overt changes in 
infected cells and the fact that LCMV buds from infected host cells, obviating the need 
for cell lysis. Neither of these points preclude the possibility that LCMV can be 
cytopathic, and certainly, not all cells are resistant to cell lysis when infected with LCMV, 
as demonstrated by the use of plaque assays on Vero cells to quantify LCMV (Ahmed et 
al., 1984). LCMV-mediated destruction of tissue is considered unlikely because viral 
disease in mice is dependent on the immune response; however, the main downstream 
effect of cell lysis could simply be the release of DAMPs that ultimately promote the 
pathogenic immune response. Considering the capability of neutrophil proteases to 
potentiate the activity of released IL-33 by orders of magnitude, it is possible that the 
effects of even small numbers of cells undergoing necrosis and releasing IL-33 could 
quickly become amplified. Nor is it difficult to envision a mechanism by which LCMV 
might induce cell necrosis. LCMV inhibits apoptosis of infected cells through the action 
of its Z protein binding to PML (Borden et al., 1998); but in the presence of death 
receptor ligands such as TNFα, inhibition of apoptosis triggers necrotic death, as 
demonstrated in vaccinia virus-infected cells (Chan et al., 2003). Thus, the possibility 
that LCMV infection of IL-33-expressing cells provides a minor trigger of necrosis and IL-
33 release cannot be excluded.  
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IL-33 and CD8+ T cells 
 Based on our work and others’, IL-33 is undoubtedly crucial for optimizing 
effector CD8+ T cell function. The reasons underlying the importance of this relationship 
are less clear. Considering the broad pro-inflammatory effects of other IL-1 family 
members, such as IL-1β and IL-18, it may seem surprising that IL-33 is the one that 
appears to have the greatest impact on CD8+ T cell responses in the context of LCMV 
infection, since IL-1 and IL-18 can both act as potent stimulators of effector CD8+ T cell 
responses in certain model systems. IL-1R signaling promotes effector differentiation of 
OT-I transgenic CD8+ T cells in mice immunized with SIINFEKL and LPS (Ben-Sasson 
et al., 2013). Like IL-33, IL-18 is a potent inducer of TCR-independent IFNγ production 
by NK cells and antigen-experienced T cells in the presence of IL-12 (Berg et al., 2003; 
Freeman et al., 2012). However, these cytokines do not appear to be as crucial to CD8+ 
T cell responses during in vivo infection, particularly with LCMV. While LCMV-specific 
CD8+ T cells in IL-1R-/- mice have reduced cytotoxic capacity, they show no defect in 
expansion (Bartholdy et al., 2009; Joeckel et al., 2012; Rahman et al., 2008). IL-18R 
signaling is dispensable for the normal kinetics of CD8+ T cell responses to vaccinia or 
Listeria monocytogenes infection (Haring and Harty, 2009) and has little to no effect on 
overall CD8+ T cell numbers in LCMV infection (Bartholdy et al., 2009; Rahman et al., 
2008). Therefore, it is possible that the importance of IL-33 reflects a particular aspect of 
the in vivo environment of LCMV or other viral infections. The abundant PAMPs provided 
by hundreds of millions of virions during a live viral infection likely provide a strong 
induction signal for IL-33 expression. In fact, the importance of the IL-33/ST2 axis in 
LCMV infection was originally identified on the basis of its high upregulation – second 
only to IFNγ among cytokines – in a genome-wide screen of LCMV-infected splenic 
tissue (Bonilla et al., 2012). The infection of countless cells by such a virus is additionally 
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likely to induce – either directly or indirectly – a great degree of cellular stress and 
necrosis, leading to substantial IL-33 release.  
Furthermore, it is possible that CD8+ T cells’ upregulation of ST2, which enables 
responsiveness to IL-33, is part of their normal effector differentiation program. This 
would imbue them with greater sensitivity to environmental cues (i.e. tissue destruction) 
and the potential to tune their responsiveness accordingly. Many viruses lyse the cells 
that they infect, making a necrosis-dependent cytokine such as IL-33 an appropriate 
signal to boost the potency of antiviral CD8+ T cell responses. Alternatively, in the setting 
of milder inflammation, where IL-33 is unlikely to be released, elevated ST2 expression 
on activated CD8+ T cells would merely be superfluous. For example, we showed in 
Chapter 5 that Il1rl1 is one of the most highly upregulated transcripts in activated IL-10+ 
hepatic CD8+ T cells, but ST2 blockade failed to alter their expansion in TLR9-MAS 
mice, or even the disease phenotype (Figure 2.7). Therefore, ST2 expression may 
provide a reserve mechanism for promoting CD8+ T cell function only in the advent of a 
severe infection.  
Differential receptor expression could also lead to some degree of specificity, in 
terms of which cells get recruited into the immune response by DAMPs released from 
necrotic cells. It is clear that DAMPs, though all pro-inflammatory in some capacity, are 
not functionally redundant. Our work demonstrated that while IL-33 signaling contributed 
significantly to FHL disease, HMGB1 had no effect. Similarly, IL-1α, another DAMP 
sequestered within cell nuclei, is likely dispensable to FHL pathophysiology because 
genetic ablation of IL-1R in FHL3 mice has no effect on mortality (Krebs et al., 2011). It 
is therefore interesting to speculate that different DAMPs have differential abilities to 
alter the nature of the inflammatory response. This could be driven by differential 
expression of DAMP receptors by immune cells, thereby impacting the particular cell 
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types eligible to be recruited into the response. The fact that ST2 appears to only be 
expressed by CD8+ T cells in the context of viral infection supports this concept (Bonilla 
et al., 2012). Likewise, differential expression of DAMPs – and thus release into the 
extracellular space only when a particular cell type undergoes necrosis – may implicate 
a certain type of pathogen or threat and direct the immune response accordingly. Future 
studies investigating the relevance of specific DAMPs to various disease models may 
therefore provide insight into the ability of DAMPs to skew inflammation towards one 
“flavor” of immune response over another. 
 
IL-33 and other inflammatory diseases 
 We have shown an important role for IL-33 in the murine model of FHL2, but it 
remains an open question whether IL-33 similarly amplifies systemic inflammation in 
other forms of hemophagocytic syndrome. Elevated IFNγ and CD8+ T cells are key 
features of all murine models of FHL, as well as several models of acquired 
hemophagocytic lymphohistiocytosis (Brisse et al., 2014), suggesting the possibility of a 
common mechanism of IL-33 driving T cell production of IFNγ in these disorders. 
However, the majority of these models rely on LCMV as a trigger of inflammation, 
making it more difficult to distinguish whether a role for IL-33 in these diseases is a 
feature of FHL itself, or simply a reflection of LCMV biology. The virus-specific CD8+ T 
cell response to several different viruses – including DNA viruses such as murine 
herpesvirus-68 – relies heavily on the IL-33/ST2 pathway, as in LCMV infection (Bonilla 
et al., 2012). Nevertheless, it will be particularly valuable to test the role IL-33 in LCMV-
independent murine FHL models, such as the Prf1-/-/murine cytomegalovirus model of 
FHL2 (van Dommelen et al., 2006), to determine whether our findings are more 
generalizable.  
109 
 
Disruption of ST2 signaling had no effect on markers of disease in TLR9-MAS 
(Figure 2.7), although the pathophysiology underlying this model differs significantly from 
that of FHL2. Hyperinflammation in TLR9-MAS mice does not require active infection or 
even the adaptive immune response (Behrens et al., 2011); furthermore, the severity of 
disease is substantially lower than in FHL2 mice, as evidenced by lower serum IFNγ 
levels, little to no weight loss, and non-lethality (Figures 2.5, 2.7, and data not shown). It 
is possible that a more severe form of the disease in which cellular necrosis may be 
more widespread, such as produced by IL-10R blockade in TLR9-MAS mice (“fulminant” 
TLR9-MAS), would show a greater dependence on the IL-33/ST2 axis. Alternatively, our 
findings may indicate basic differences in the pathophysiology of FHL compared to MAS. 
 It is also quite possible that the IL-33/ST2 axis is pathogenic in inflammatory 
disorders that are not typically classified as hemophagocytic syndromes but which share 
their cytokine storm physiology. In particular, hemophagocytic syndromes are strikingly 
similar to viral hemorrhagic fevers (VHF), such as those caused by infection with Ebola, 
hanta, dengue, yellow fever, Hendra, Nipah, and Crimean-Congo hemorrhagic fever 
viruses (Paessler and Walker, 2013). This has led some to speculate that VHF actually 
represents secondary, or reactive, hemophagocytic syndrome triggered by a viral 
infection (Cron et al., 2015; van der Ven et al., 2015). Both hemophagocytic syndrome 
and VHF are characterized by fever, vascular leakage, hemodynamic instability, liver 
dysfunction, DIC, cytopenias, hemophagocytosis, and extraordinary hyperferritinemia  
(Cron et al., 2015). Highly elevated levels of inflammatory cytokines and chemokines, 
such as IFNγ, TNFα, IL-6, IL-1α, IL-18, MCP-1, MIP-1α, as well as counter-regulatory 
cytokines such as IL-10, provide evidence of dysregulated immune hyperactivation in 
VHF (Misasi and Sullivan, 2014; van der Ven et al., 2015). It is worth noting, however, 
that unlike FHL, a key feature of VHF is often severe T and NK lymphopenia, with 
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relatively little immune cell infiltration into the liver and other organs (Paessler and 
Walker, 2013). In Ebola virus infection, this results from both viral antagonism of APC 
function, leading to defective T cell priming, and massive induction of T cell apoptosis 
(Baize et al., 1999; Misasi and Sullivan, 2014). Such observations suggest that the 
primary cells promoting inflammation may differ between VHF and hemophagocytic 
syndrome. 
Nevertheless, it is worth considering whether IL-33 or other DAMPs could play a 
crucial immunostimulatory role in VHF, as well as in hemophagocytic syndromes. Ebola 
virus is capable of infecting endothelial cells, epithelial cells, fibroblasts, and other IL-33-
expressing cells, providing a potential trigger of IL-33 release (Paessler and Walker, 
2013). Furthermore, extensive necrosis is observed throughout multiple organs in fatal 
cases of Ebola virus disease, suggesting large-scale release of DAMPs and other 
inflammatory mediators (Martines et al., 2015). Consistent with this, serum levels of IL-
1α are elevated in both humans and rhesus macaques infected with Ebola virus (van der 
Ven et al., 2015). Moreover, the IL-33/ST2 pathway has already been implicated in 
hanta and dengue infections (Becerra et al., 2008; Guerrero et al., 2013; Zhang et al., 
2015). Further investigation of the inflammatory mediators driving immune dysregulation 
in VHF should therefore consider DAMPs such as IL-33 and explore whether 
immunomodulation of these pathways might mitigate the clinical effects of cytokine 
storm in patients. Ultimately, it will be important to determine whether α-ST2 therapy 
could benefit a broader range of inflammatory diseases than the type 2 immune-
mediated disorders with which IL-33 is classically identified. 
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Hepatic CD8+ T cells and systemic inflammation 
 In Chapter 5, we identified an unusual CD8+ T cell population infiltrating the livers 
of mice with cytokine storm. These effector-like cells were induced independently of 
antigen stimulation to produce IL-10 and accumulate in damaged liver; indeed, their 
transcriptional profile suggested responsiveness to hepatic growth factors released upon 
liver injury. While these IL-10+ hepatic CD8+ T cells paradoxically possessed features 
typical of both pathogenic and protective cells, their predominance in the liver in the 
context of systemic inflammation was intriguing. Liver histopathology in patients with 
FHL and MAS is likewise characterized by an extensive CD8+ T cell infiltrate (Billiau et 
al., 2005; Chen et al., 2010), demonstrating an important parallel to murine models.  
 The liver is disproportionately affected in FHL and MAS, suggesting that it is a 
unique target of systemic inflammation. The guidelines for MAS complicating sJIA 
support this concept, citing elevated aspartate aminotransferase among the diagnostic 
criteria (Ravelli et al., 2016). While the criteria for FHL do not formally include hepatitis, 
they note that clinical, laboratory, or histologic evidence of hepatic inflammation strongly 
supports the diagnosis (Henter et al., 2007). By some estimates, transaminitis is 
observed in >30% patients with hemophagocytic lymphohistiocytosis at initial 
presentation (Janka, 2012), and severe hepatic dysfunction is frequently the 
predominant clinical feature. In a subset of cases, liver failure can even be the 
presenting symptom of hemophagocytic syndrome (Abdullatif et al., 2016; Amin et al., 
2013; Schneier et al., 2016), leading some to speculate that acute liver failure not 
attributable to known causes may actually be a manifestation of hemophagocytic 
syndrome (DiPaola et al., 2014). 
Indeed, mounting evidence suggests that FHL bears striking resemblance to 
pediatric acute liver failure of indeterminate origin (iPALF), a sizable subset of acute liver 
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failure cases among children in which the etiology eludes specific diagnosis (Squires et 
al., 2006). iPALF is a diagnosis of exclusion, fulfilling the clinical criteria for acute liver 
failure but inconsistent with known causes, such as acetaminophen toxicity, inherited 
metabolic disease, autoimmune hepatitis, or acute viral hepatitis (Squires, 2008). While 
mechanistic understanding of the disease pathogenesis of iPALF is critically lacking, 
there is increasing reason to suspect that dysregulated inflammatory processes, similar 
to those in FHL, may underlie a large portion of cases. Elevated serum levels of sCD25, 
a marker of T cell activation, are found in approximately half of iPALF patients 
(Bucuvalas et al., 2013). There is also substantial clinical overlap between iPALF and 
FHL, including fever, hepatomegaly, transaminitis, and bone marrow suppression 
(DiPaola et al., 2014). Remarkably, a recent histologic analysis of liver biopsies from 
iPALF patients identified a predominant CD8+ T cell infiltrate in the majority of cases 
(Chen et al., 2010; McKenzie et al., 2014), similar to findings in FHL and MAS. Together, 
these observations suggest the possibility of a common immunologic mechanism 
responsible for liver injury in both hemophagocytic syndrome and iPALF. 
Our identification of activated CD8+ T cells in the livers of mice with 
hemophagocytic syndrome therefore provides a model with which to dissect the role of 
liver-infiltrating CD8+ T cells in systemic inflammation. It has long been noted that TCR 
stimulation, whether polyclonal or specific, induces the rapid accumulation of CD8+ T 
cells in the liver (Belz et al., 1998; Huang et al., 1994; Mehal et al., 1999; Wherry et al., 
2003). Antigen-independent signals clearly contribute to this effect, as evident by the 
TLR4-dependence of TCR-activated CD8+ T cell trapping in one model (John and 
Crispe, 2005). However, our data demonstrate that antigen-independent signals 
themselves are sufficient for liver infiltration by activated CD8+ T cells and suggest that 
the TLR9-MAS model is ideal for studying this phenomenon. Furthermore, viral triggers 
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are frequently suspected, but often never identified, in many cases of hemophagocytic 
syndrome and iPALF, even after thorough deep-sequencing analysis of sera (Schwarz 
et al., 2014). The antigen-independent induction of IL-10+ effector CD8+ T cells in the 
livers of TLR9-MAS mice leads us to speculate that activated IL-10+ CD8+ T cells 
innately induced to produce cytokine may represent an alternative explanation for cases 
of viral-like hepatitis but lack of identifiable antigen. Further study of the IL-10+ hepatic 
CD8+ T cell subset we identified may therefore provide insight into the impact of hepatic 
CD8+ T cells in iPALF and hemophagocytic syndromes.  
At present, it is unclear whether these cells are causative of liver injury or are 
merely epiphenomena. IL-10+ hepatic CD8+ T cells in TLR9-MAS mice showed the 
transcriptional signature of highly activated effector cells and possessed several 
potentially pathogenic capabilities, including IFNγ production and elevated expression of 
FasL. Thus, despite concurrent production of IL-10, these features suggest the 
possibility that IL-10+ hepatic CD8+ T cells contribute to liver damage. It will be valuable 
to determine whether the hepatic CD8+ T cells observed in iPALF patients are also 
members of this unique subset and similarly harbor destructive potential. Future 
investigation of the CD8+ T cells in patients with iPALF or hemophagocytic syndrome, as 
well as the effector IL-10+ hepatic CD8+ T cells in murine TLR9-MAS, will therefore be 
important to determine their potential role in disease pathogenesis. 
 
Conclusion 
 In summary, we have shown that the contribution of antigen-independent signals 
to CD8+ T cell activation is essential to the pathophysiology of hemophagocytic 
syndromes. DAMPs such as IL-33 enhance the expansion and IFNγ production of CD8+ 
T cells in the murine model of FHL2, promoting immune dysregulation and mortality. 
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PAMPs such as CpG induce the accumulation of cytokine-producing effector-like CD8+ T 
cells within damaged liver. It is our hope that future investigation will build upon the 
findings presented here to expand insight into the role of danger signals in cytokine 
storm syndromes and suggest additional sources of immune dysregulation that may be 
targeted therapeutically. 
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APPENDIX: 
Materials and Methods 
 
Mice  
C57BL/6 (WT), perforin-deficient (C57BL/6-Prf1tm1Sdz/J, referred to as Prf1-/-), B6.SJL 
(B6.SJL-PtprcaPepcb/BoyJ), tiger (B6.129S6-Il10tm1Flv/J, referred to as IL-10 reporter) 
(Kamanaka et al., 2006), OT-I (C57BL/6-Tg(TcraTcrb)1100Mjb/J), and IFNGR-deficient 
(B6.129S7-Ifngr1tm1Agt/J, referred to as Ifngr-/-) mice were purchased from The Jackson 
Laboratory and bred in our facility. Myd88-/- mice were a kind gift from Lawrence Turka 
(The Children’s Hospital of Philadelphia) and were crossed to Prf1-/- mice (Adachi et al., 
2000). Il1rl1-/- mice, originally derived from Andrew McKenzie (University of Cambridge) 
(Townsend et al., 2000) and back-crossed to C57BL/6, were kindly provided by Peter 
Nigrovic (Harvard University) as heterozygotes and bred to homozygosity in our facility. 
Il33-/- mice were provided by Amgen (Ngoi et al., 2012). Rag1-/- mice were a kind gift of 
Paula Oliver (The Children’s Hospital of Philadelphia). For data in Chapters 3 and 4, 
Il1rl1-/- and B6.SJL mice were crossed to Prf1-/- mice. For data in Chapter 5, B6.SJL, OT-
I, Prf1-/-, and Ifngr-/- mice were crossed to IL-10 reporter mice. In Chapter 5, unless 
otherwise stated, WT refers to IL-10 reporter mice. All mice were bred and housed in an 
Association for Assessment and Accreditation of Laboratory Animal Care–certified 
animal facility, and all experiments were performed with approval of the University of 
Pennsylvania and The Children’s Hospital of Philadelphia Institutional Animal Care and 
Use Committees. 
 
Viral infection 
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Armstrong and Clone 13 strains of LCMV were kindly provided by E. John Wherry 
(University of Pennsylvania). To induce FHL, mice aged 7-9 weeks were infected 
intraperitoneally with 2×105 PFU LCMV-Armstrong and were euthanized upon 
development of significant morbidity or weight loss. In Chapter 5, Prf1-/- IL-10 reporter 
mice were infected with 1×105 PFU LCMV-Armstrong i.p. and analyzed 11 days p.i. In 
Chapter 4, WT and Il1rl1-/- mice were infected with 4×106 PFU LCMV-Clone 13 by retro-
orbital i.v. injection. Viral titers were measured by plaque assays on Vero cells as 
previously described (Ahmed et al., 1984). Unless otherwise specified, LCMV refers to 
LCMV-Armstrong. 
 
Induction of TLR9-MAS 
Mice were injected i.p. with 50 µg CpG ODN 1826 on days 0, 2, 4, 7, and 9; control mice 
were injected i.p. with PBS on the same dosing schedule. All TLR9-MAS and control 
mice were euthanized on day 10.  
 
In vivo treatments 
Rat anti-mouse ST2-blocking antibody with muIgG1 Fc domain (α-ST2 antibody) and 
mouse IgG1 isotype control antibody were provided by Amgen and have been previously 
described (Palmer et al., 2009). For ST2 blockade in FHL2 mice, LCMV-infected mice 
were injected intraperitoneally with 150 µg α-ST2 antibody or 150 µg Control antibody 
every other day, beginning on day 3 p.i. Withdrawal from ST2 blockade was achieved by 
switching mice to Control antibody treatment at the specified timepoint. For ST2 
blockade in TLR9-MAS, mice received 150 µg α-ST2 antibody or 150 µg Control 
antibody i.p. concurrently with the last four CpG injections. 
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α-HMGB1 antibody (clone 2G7) and IgG2b isotype control antibody was kindly provided 
by Ulf Andersson (Karolinska Institutet) (Qin et al., 2006). For HMGB1 blockade, LCMV-
infected mice were injected intraperitoneally with 50 µg α-HMGB1 antibody or 50 µg 
Control antibody every three days, beginning on day 3 p.i. 
 
α-PD-L1 antibody (clone 10F.9G2) and rat IgG2b isotype control antibody were 
purchased from BioXCell (Barber et al., 2005). For PD-L1 blockade, LCMV-infected mice 
were injected intraperitoneally with 200 µg α-PD-L1 antibody or 200 µg Control antibody 
every three days, beginning on day 15 p.i. 
 
BM chimeras 
In Chapter 3, irradiated CD45.2+ Rag1-/- hosts received BM from CD45.1+ Prf1-/- donors, 
CD45.2+ Prf1-/-Il1rl1-/- donors, or a 1:1 mixture of both. Six weeks after transfer, mice 
were cheek bled to check for T cell reconstitution. Eight weeks after transfer, chimeras 
were either left uninfected or were infected intraperitoneally with 2×105 PFU LCMV-
Armstrong; all mice were analyzed on day 8 p.i.  
 
In Chapter 5, irradiated B6.SJL (CD45.1+) hosts received BM from CD45.1/2+ IL-10 
reporter donors (WT), CD45.2+ Ifngr-/- IL-10 reporter donors (Ifngr-/-), or both. For the 
mixed BM chimeras, a 9:1 mix of WT and Ifngr-/- cells was used to ensure there was 
adequate IFNγ response present to induce TLR9-MAS. After waiting 12 weeks for 
reconstitution, chimeras received 5 doses of either PBS or CpG i.p. and were analyzed 
on day 10. 
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Tissue analysis 
Peripheral blood was obtained by cheek bleed and complete blood cell counts were 
performed on a Hemavet analyzer (Drew Scientific). Serum ferritin, sCD25, and IFNγ 
were measured using ELISA (ALPCO, R&D Systems, and BD Biosciences, 
respectively).  
 
Unperfused organs were fixed overnight in 10% formaldehyde and embedded in 
paraffin. Liver and spleen sections were stained with hematoxylin and eosin. 
Deparaffinization, retrieval, and immunohistochemistry were done on the Leica Bond III 
Autostainer using the Bond Polymer Refine Detection System (Leica Microsystems). IL-
33 goat primary antibody (R&D Systems) was run at a 1:30 dilution after epitope retrieval 
with ER2 buffer (Leica), and rabbit anti-goat secondary antibody (Jackson 
ImmunoResearch Labs) was added. Slides were read by pediatric pathologists (Michele 
Paessler, Portia Kreiger) blinded to treatment protocols. Images were acquired on an 
Eclipse 90i microscope (Nikon) using a 20X (NA 0.75) Plan Apochromatic objective and 
NIS Elements BR 4.13.04 software. 
 
Quantitative real time PCR 
RNA was isolated from RNAlater-preserved tissues using the RNeasy Mini kit (Qiagen), 
converted to cDNA using the Superscript III First-Strand Synthesis System (Life 
Technologies), and subjected to qPCR using QuantiTect primers for Actb, Il33, and Il1rl1 
(Qiagen) and Power SYBR Green master mix (Life Technologies). Results were 
normalized to β-actin using the ΔΔCT method. 
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Analysis of human gene expression 
Published data sets (GSE26050, GSE21521) were accessed through NCBI Gene 
Expression Omnibus. Raw CEL files from both data sets were normalized together using 
Robust Multi-array Average in RMA Express. 
 
Microarrays and transcriptional analysis 
Paired IL-10- and IL-10+ populations were sorted from among the live CD44+ hepatic 
CD8+ T cell pools from four TLR9-MAS IL-10 reporter mice into RLT Buffer, and RNA 
was isolated using the RNeasy Micro Kit (Qiagen). Quality assessment of purified RNA, 
amplification, hybridization to GeneChip Mouse Gene 1.0 ST arrays (Affymetrix), and 
data collection was performed by the Nucleic Acid/Protein Research Core Facility at The 
Children’s Hospital of Philadelphia. Microarrays were preprocessed using robust 
multiarray analysis (RMA). Probe sets lacking gene symbol annotation or with a mean 
log2 intensity of <5 among the IL-10+ samples were filtered out. Log2-transformed 
expression data were analyzed using R statistical computing language. Hierarchical 
clustering of IL-10- and IL-10+ samples was performed using GenePattern (Broad 
Institute). Differentially expressed genes were defined as those with at least 1.5-fold 
difference in expression in IL-10+ as compared to IL-10- cells and statistical significance 
using paired Student’s t-test, with a false discovery rate <0.2. Pathway analysis was 
performed using Ingenuity Pathway Analysis (Qiagen). Putative upstream regulators with 
an activation z-score of >2 or <-2 and a p-value of <5x10-5 were considered significant. 
Comparison to ImmGen data sets [(Best et al., 2013) and GEO Accession# GSE15907] 
was performed by John Tobias by: 1) RMA normalizing the raw data from all 36 
samples; 2) using ComBat (Johnson et al., 2007) to correct for the predicted (and 
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subsequently demonstrated) batch effect between our samples and the ImmGen set; 3) 
performing one-way ANOVA on the ImmGen samples only to select the top 500 genes 
on their ability to separate the ImmGen time points (lowest p-values for one-way 
ANOVA); 4) filtering data for all samples to include only these 500 genes; 5) averaging 
data for all replicates of each condition; 6) performing per gene normalization 
(subtracting median expression across all conditions of each gene from its value in each 
condition); 7) clustering (average linkage) using Spearman (rank) similarity metric. 
Analysis of Il10 expression in GP33-specific CD8+ T cells after LCMV infection was 
performed on data from GEO Accession #GSE41867 (Doering et al., 2012) using 
GEO2R (National Center for Biotechnology Information). 
 
Flow cytometry 
Spleens and livers were harvested, homogenized, and passed through a 70µm filter to 
generate single cell suspensions. Hepatic leukocytes were isolated by Percoll density 
gradient centrifugation (GE Healthcare Life Sciences). Red blood cells were osmotically 
lysed using ACK Lysis Buffer (Lonza). Cell concentrations were assessed using a 
hemocytometer or a Countess Automated Cell Counter (Invitrogen, ThermoFisher 
Scientific). Cells were stained with LIVE/DEAD fixable viability dye (Invitrogen, 
ThermoFisher Scientific) and Fc blocked (clone 2.4G2, produced in house) prior to 
surface antibody staining. Fluorochrome-tagged antibodies targeting B220, CD4, CD8α, 
CD8β, CD19, CD25, CD44, CD45.1, CD45.2, CD62L, CD69, CD90.2, CD122, CD127, 
KLRG1, NK1.1, TCRβ, and Vβ5.1/5.2 were obtained from BD Biosciences, eBioscience, 
BioLegend, and Miltenyi Biotec. H-2DbGP33-41 and I-AbGP66-77 MHC-peptide complexes 
were provided as fluorophore-conjugated tetramers by E. John Wherry and the NIH 
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Tetramer Core Facility, respectively. Data were acquired using BD LSR II and Miltenyi 
Biotec MACSQuant flow cytometers and analyzed using FlowJo software versions 9.8, 
9.9, or X.07 (FlowJo, LLC).  
 
Intracellular staining 
All staining of intracellular molecules was performed on cells stained with LIVE/DEAD, 
Fc blocked, and stained for surface antigens immediately prior. For intracellular cytokine 
staining, cells were stimulated in vitro, as indicated below, before fixation, 
permeabilization, and intracellular cytokine staining using the Cytofix/Cytoperm kit (BD 
Bioscience). Cells stained for transcription factors and Ki-67 were fixed and 
permeabilized using the Foxp3/Transcription Factor Fixation/Permeabilization kit 
(eBioscience). Fluorochrome-tagged antibodies targeting Eomesodermin, Foxp3, IFNγ, 
IL-10, IL-2, Ki-67, T-bet, and TNFα were obtained from BD Biosciences, eBioscience, 
and Miltenyi Biotec. 
 
For LCMV peptide restimulation assays in Chapters 2-4, 106 splenocytes were cultured 
in the absence or presence of LCMV gp33 peptide (0.2 µg/ml, GenScript) or LCMV gp61 
peptide (1.0 µg/ml, Anaspec) and brefeldin A (Sigma) for 5 hours at 37°C. In assays 
measuring degranulation, PE-conjugated CD107a antibody and monensin were also 
included in culture medium for the duration of the stimulation. In Figure 4.1, a pool of 
LCMV peptides representing major CD8+ T cell epitopes, kindly provided by E. John 
Wherry, was used for the stimulation. The frequency of cytokine+ LCMV-specific cells 
was calculated as (%cytokine+ with peptide) – (%cytokine+ without peptide).  
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For intracellular cytokine staining in Chapter 5, hepatic leukocytes from TLR9-MAS IL-10 
reporter mice were plated in the presence of PMA, ionomycin, and Brefeldin A (Sigma-
Aldrich) for 5 hours. For staining of intracellular markers, hepatic T cells were MACS-
purified using CD90.2 Microbeads (Miltenyi Biotec), sorted into IL-10/GFP+ and IL-
10/GFP- CD8+ T cell populations on a BD FACS Aria II, and fixed/permeabilized prior to 
staining. To generate comparator naïve CD8+ T cells, splenic T cells were MACS-
purified from PBS-injected WT mice using CD90.2 Microbeads, stained, and gated on 
CD44-CD8+ T cells. To generate comparator effector CD8+ T cells, splenic T cells were 
similarly MACS-purified from C57BL/6 mice 8 days post-infection with 2x105 PFU LCMV-
Armstrong i.p., stained, and gated on CD44+CD8+ T cells. 
 
Viability assays 
In Chapter 3, initiation of apoptosis was measured by incubation with Vybrant FAM-
DEVD-FMK caspase-3 and -7 reagent, referred to as FLICA (fluorescent inhibitor of 
caspases), according to manufacturer instructions (Life Technologies). Cells were 
subsequently stained for surface markers.  
 
In Chapter 5, cells for viability assays were pooled from four to six TLR9-MAS IL-10 
reporter mice and isolated by FACS as live (LIVE/DEAD-negative) IL-10/GFP+ or IL-
10/GFP- hepatic CD8+ T cells, or live naïve (CD44-) splenic CD8+ T cells. BM-derived 
dendritic cells (BMDC) were generated by culturing C57BL/6 BM cells in media with 
granulocyte/macrophage colony-stimulating factor (3.3 ng/mL) for 10 days. Live IL-
10/GFP+ and IL-10/GFP- hepatic CD8+ T cells were plated either with or without BMDC 
and CpG (10 µg/mL) in 96-well flat-bottom plates at 37°C for 12-16 hours, then re-
stained with LIVE/DEAD and assessed for viability by forward scatter (FSC) and 
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LIVE/DEAD. For the viability timecourse, live IL-10/GFP+ and IL-10/GFP- hepatic CD8+ T 
cells and naïve splenic CD8+ T cells were plated in complete media in 96-well flat-bottom 
plates at 37°C, either alone or with plate-bound α-CD3/α-CD28, recombinant IL-2 (50 
U/mL), recombinant IL-12 (0.5 ng/mL), or serum from a C57BL/6 TLR9-MAS mouse (10-
fold diluted). After 6, 12, or 24 hours in culture, cells were re-stained with LIVE/DEAD 
and assessed for viability by FSC and LIVE/DEAD. 
 
Statistical Analysis 
Weight loss data and T cell data in Chapter 2 were analyzed by linear mixed-effects 
models using R (R Core Team, 2014) and lme4 (Bates et al., 2014), as indicated in 
figure legends. Visual inspection of residual plots did not reveal any obvious deviations 
from homoscedasticity or normality. P values were obtained by likelihood ratio tests of 
the full model with the effect in question against the model without the effect in question. 
We used the method of Levy (Levy, 2014) to obtain tests of main effects while modeling 
an interaction effect. All other data were analyzed in GraphPad Prism 5 using statistical 
tests indicated in figure legends. Unless otherwise specified, P values are represented in 
figures by number of symbols (e.g. * P<0.05, ** P<0.01, *** P<0.001). 
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